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Functional Bowel Disorders Classification 
Functional bowel disorders (FBDs) are a spectrum of chronic gastrointestinal disorders, 
attributable to the middle or lower gastrointestinal tract, characterized by the following 
predominant symptoms or signs: abdominal pain, abdominal bloating, abdominal distension 
and bowel habit abnormalities (which include constipation, diarrhea, or mixed constipation 
and diarrhea).  Functional bowel disorders (FBDs) can be classified into 5 distinct categories: 
irritable bowel syndrome (IBS); functional constipation (FC); functional diarrhea (FDr); 
functional abdominal bloating/distention (FAB/D); and unspecified FBD (U-FBD). Although 
categorized as distinct disorders, significant overlap exists, and in some cases it may not be 
possible to confidently distinguish them. The FBDs can be conceptualized in 3 ways (see Figure 
1): 1. As distinct conditions that occur independently; 2. As distinct pathophysiologic 
conditions with symptoms that frequently overlap; and 3. As a spectrum of pathophysiologic 
disorders that frequently overlap and which are characterized by patient specific differences in 
the quantity, intensity and severity of symptom expression. The opinion of this committee is 
that the third conceptual framework is the one that best explains FBDs (Figure 1). 
 
Figure 1. Conceptual framework to explain Functional Bowel Disorders 
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Patients with FBDs commonly transition from one FBD diagnostic group to another 
over time. This may be due to the natural history of the disorder, a response to therapy, or 
both. For clinical trials it is recommended that patients belong unequivocally to only a single 
diagnostic category, unless the investigation is focused specifically on overlapping FBDs. In 
some cases, a patient may not fulfill diagnostic criteria for any of the 4 specific FBDs 
categories, in which case the patient should be considered to have an unspecified FBD (U-FBD). 
The operational construct described below distinguishes FC and IBS with constipation 
as distinct disorders; cluster analysis studies support this separation.1,2 Others believe, 
however, that both are part of a spectrum, with constipation as a predominant symptom and 
abdominal pain as a second symptom of variable intensity.3-5 Considerable overlap exists 
between IBS-C and FC when mutual exclusivity is suspended.6 Transition from FC to IBS-C, or 
vice versa, is common.3, 7 The similarities of the 2 disorders suggest that IBS-C and FC should be 
considered separate ends of a spectrum8 (Figure 1). 
Functional diarrhea (FDr) and IBS-D represent a similar situation.  In a minority of 
cases, diarrhea happens in the absolute absence of abdominal pain and should unequivocally 
be diagnosed as FDr. When mutual exclusivity was suspended, overlap between FDr and IBS-D 
occurred in 28% of cases.6 The diagnosis of these 2 disorders should be made based on the 
predominant symptom: FDr if diarrhea is clearly the predominant symptom and IBS-D if 
diarrhea is present but abdominal pain predominates (Figure 1). 
Functional abdominal bloating and distension are independent and specific FBDs only 
when present as the predominant symptom in the absence of other gastrointestinal 
symptoms. Functional abdominal bloating (FAB) and distension (FAD) should be classified as a 
single entity (FAB/D) although they encompass two different symptoms/signs: Abdominal 
bloating is the subjective sensation of abdominal pressure, fullness, and/or gassiness, while 
distention is the objective and measurable increase in abdominal girth. These conditions may 
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exist independently although they frequently coincide in the same individual.9, 10 The distinct 
nature of these disorders is demonstrated by research showing that only 50-60% of patients 
with bloating have abdominal distension and the correlation between abdominal bloating and 
an increase in abdominal girth is poor.11, 12 Further research may allow FAB and FAD to be 
considered separate entities.  
 
KEY POINTS 
 The following points highlight notable changes from Rome III: 
• FBDs are considered a spectrum of disorders rather than isolated entities.  
• Distinguishing different FBDs may not be easy as overlap commonly exists. 
• The transition from one FBD to another, or from one predominant symptom to another, 
is common and may occur due to the natural history of the disorder, a response to 
therapy, or both. 
• Abdominal bloating and distention remain a single entity, although they do not always 
co-exist, and they likely have different pathophysiological origins. 
 
Patient Classification 
Subjects with FBDs can be divided into 2 major groups: 
A. Non-patients. Those with mild symptoms (or not bothersome or worrisome enough) who 
have not sought medical attention for their FBD symptoms. 
B. Patients. Those with symptoms severe enough (or bothersome or worrisome enough) to 
seek out medical attention for their FBD symptoms. 
Not every individual with FBD symptoms should be considered a patient as these 
symptoms are frequent in the general population. The difference between patients and non-
patients is related not only to symptom severity (e.g., intensity, frequency, unpredictability) 
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and medical consultation, but also to other factors such as fears and worries, impact on quality 
of life, co-existing medical and psychological disorders, learned behavior, and access to health 
care services.  
 
KEY POINTS 
The following points highlight notable changes from Rome III: 
•  Not every individual with FBD symptoms should be considered a patient. 
• A clearer distinction between patient and non-patients is proposed. This is especially 
relevant for epidemiological studies. 
 
C1. IRRITABLE BOWEL SYNDROME 
Definition 
Irritable bowel syndrome (IBS) is a functional bowel disorder in which recurrent 
abdominal pain is associated with defecation or a change in bowel habits. Disordered bowel 
habits are typically present (constipation, diarrhea or a mix of constipation and diarrhea), as 
are symptoms of abdominal bloating/distension.  
Symptom onset should occur at least 6 months prior to diagnosis and symptoms should 
be present during the last 3 months.  
 
Epidemiology 
 Prevalence and incidence rates of IBS vary from country to country based on the 
survey population, the criteria used to define IBS and the type of survey instrument employed.  
A meta-analysis of 80 studies involving 260,960 subjects identified a prevalence rate of 11.2% 
(95% CI, 9-8%-12.8%).13 Two separate longitudinal population studies lasting 10 and 12 years 
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reported the development of IBS symptoms in 15% and 16.2% of the population, yielding 
calculated incidence rates of 1.5% and 1.35%, respectively.14, 15 Prevalence rates are higher for 
women than for men; younger people are more likely to be affected than those older than age 
50.13 There are insufficient data to assess the impact of socioeconomic status on the 
development of IBS symptoms. 
  A systematic review noted that 12-18% of patients became symptom free during a 
median follow-up period of 2 years, while 32-68% had unchanged or a worsening of IBS 
symptoms16. A longitudinal population study reported that 67% (95% CI, 61-73%) of patients 
symptomatic at baseline had persistent IBS symptoms, using Manning criteria.14 Longitudinal 
population studies have shown that 32-68% of IBS patients have persistent symptoms at up to 




The following points highlight notable changes from Rome III: 
C1. Irritable Bowel Syndrome 
Diagnostic criteria* 
Recurrent abdominal pain on average at least 1 day/week in the last 3 months, 
associated with two or more of the following criteria: 
1. Related to defecation 
2. Associated with a change in frequency of stool 
3. Associated with a change in form (appearance) of stool 
* Criteria fulfilled for the last 3 months with symptom onset at least 6 months 




• Abdominal discomfort has been deleted from the definition. It was the opinion of this 
committee that the imprecise nature of the term “discomfort” coupled with the fact 
that “discomfort” is not present in every language warranted its removal. 
• Abdominal pain should be present at least 1 day per week on average during the 
preceding 3 months.1 
• Bloating/distention are recognized as common symptoms.  
•  “… and with features of disordered defecation” has been replaced by “… disordered 
bowel habits are typically present (constipation, diarrhea or a mix of constipation and 
diarrhea)”. 
• “Criteria present for the last 3 months and onset at least 6 months prior to diagnosis” 
has been replaced by: “Symptom onset should occur at least 6 months prior to 
diagnosis and symptoms should be present during the last 3 months”. The first criterion 
is meant to emphasize the specific FBD as a chronic disorder and to decrease the 
probability of an organic disease. The second criterion requires that symptoms be 
present recently.  
 
Justification for Change in Criteria 
The presence of abdominal pain is mandatory to make the diagnosis of IBS.  A diagnosis of IBS 
cannot be made if abdominal pain is absent. The term “discomfort” has been deleted from the 
current definition and diagnostic criteria because some languages do not have a word for 
discomfort or it has different meanings in different languages. Additionally, it is unclear 
whether the distinction between pain and discomfort is qualitative or quantitative. This is 
based on a study of IBS patients (n = 123) who reported that abdominal pain and discomfort 
were different,17 but exhibited wide variations in their understanding of these terms. They 
reported that discomfort encompassed a wide range of symptoms such as bloating, gas, 
 




fullness, flatulence, sensation of incomplete evacuation or urgency. Another study concluded 
that “abdominal discomfort or pain” is an ambiguous term because no agreement could be 
reached on whether these are qualitatively different sensations.18 In 328 IBS patients only one-
half rated the frequency of pain alone (53%), and discomfort alone (55%), as identical in 
intensity. However, in 4 of 5 cases the same individual would be diagnosed with IBS regardless 
of which descriptor was used. Therefore, the current guidelines will not include the term 
abdominal discomfort, but will instead emphasize the more globally recognized term of 
abdominal pain. Non-pain symptoms should also be carefully specified rather than grouping 
them in this misleading term.  
IBS Subtypes 
IBS is classified into 3 main subtypes according to the predominant disorder in bowel 
habits: IBS with predominant constipation (IBS-C), IBS with predominant diarrhea (IBS-D) and 
IBS with mixed bowel habits (IBS-M). The committee appreciates the complexity of subtyping 
IBS patients and for clinical practice suggests that subtyping be based on the patient’s reported 
predominant bowel habit on days with abnormal bowel movements.  IBS subtypes should be 
established according to stool consistency, using the Bristol Stool Form Scale (Figure 2).19 For 









The following points highlight notable changes from Rome III: 
• IBS remains divided into 4 subtypes (IBS-C, IBS-D, IBS-M and IBS-U), although it is 
recognized that pain or bloating/distention may predominate in some patients. 
• Predominant bowel habits are based on stool form on days with abnormal bowel 
movements. IBS subtypes related to bowel habit abnormalities (IBS-C, IBS-D and IBS-M) 
can only be confidently established when the patient is evaluated off medications used 
to treat bowel habit abnormalities.  
• For clinical trials, subtyping based on at least 2 weeks of daily diary data is 
recommended. 
 
IBS Bowel Habit Subtype Criteria 
Diagnostic criteria 
Predominant bowel habits are based on stool form on days with abnormal bowel 
movements.*  
IBS with predominant constipation (IBS-C): > ¼ (25%) of bowel movements with 
Bristol stool types 1 or 2 and < ¼ (25%) bowel movements with Bristol stool types 6 or 
7. 
IBS with predominant diarrhea (IBS-D): > ¼ (25%) of bowel movements with Bristol 
stool types 6 or 7 and < ¼ (25%) bowel movements with Bristol stool types 1 or 2. 
IBS with mixed bowel habits (IBS-M): > ¼ (25%) of bowel movements with Bristol 
stool types 1 or 2 and > ¼ (25%) bowel movements with Bristol stool types 6 or 7. 
IBS Unclassified (IBS-U): Patients who meet diagnostic criteria for IBS but whose bowel 
habits cannot be accurately categorized into 1 of the 3 groups above should be 
categorized as having IBS-U. 
*IBS subtypes related to bowel habit abnormalities (IBS-C, IBS-D and IBS-M) can only be 
confidently established when the patient is evaluated off medications used to treat bowel habit 
abnormalities.  









To have confidence in subtyping, patients should have at least 4 days of abnormal 
bowel habits each month.2. Bowel habit subtypes should be based on Bristol Stool Form Scale 
(Figure 2) for days with abnormal bowel habits. Analysis of days without a bowel movement 
does not increase the specificity of bowel subtyping, while analyzing only days with abnormal 
bowel movements increases it.2 Careful analysis of bowel diaries, using different cut points, 
determined that the 25% value for stool abnormalities most accurately categorized patients 
into subtypes, and minimized the number of patients categorized as having the unclassified 
subtype.  These recommendations are based on normative data from population studies and 
from clinical studies demonstrating that a large proportion of IBS patients have bowel 
movements that are within the normal range of stool consistency3. The diagnosis of IBS 
subtype should also take into account the patient’s perception of their predominant bowel 
habits. Evaluation (subjective opinion and/or data from the Bristol scale) has to be performed 
with the patient off all therapies for bowel habit abnormalities (including laxatives and 
antidiarrheal agents).21 The categories are considered mutually exclusive. 
For clinical purposes, with the goal of providing a coherent treatment approach to 
health care providers, and for clinical trial design, the predominance of abdominal pain (P) and 
abdominal bloating/distension (AB/D) should be taken into account. Thus, although not 
included as classical IBS subtypes, some patients might be categorized as IBS-P or IBS-AB/D.   
 
Diagnosis of IBS 
IBS diagnostic criteria, like other diagnostic criteria, are not completely foolproof. The 
diagnosis of IBS requires common sense, physician thoughtfulness, limited diagnostic tests and 
careful follow-up.  The decision to pursue diagnostic testing is predicated on a number of 
 





factors (e.g., alarm features, co-morbid conditions, refractoriness to therapy, cost of tests, 
insurance plans, etc.). The goal of diagnostic criteria is to provide a readily useable framework 
that can be easily applied, recognizing that no single test, and no single definition, is perfect.22 
For example, it is now evident that some organic bowel disease may fulfill IBS criteria.6 
Since a number of conditions have symptoms that can mimic IBS (e.g., inflammatory 
bowel disease [IBD], celiac disease, lactose intolerance, and microscopic colitis) limited testing 
may be required to accurately distinguish these disorders. However, for the majority of 
patients, when diagnostic criteria for IBS are fulfilled, and alarm features are absent, the need 
for diagnostic tests should be minimal.23 Routine follow-up visits with targeted diagnostic 
studies for the persistently symptomatic patient appear cost-effective approach and may be 
more reassuring to the patient. The Rome IV committee encourages clinicians to make a 
positive diagnosis on the basis of symptoms and emphasizes that IBS is not a diagnosis of 
exclusion. It is worth emphasizing that when ordering a diagnostic test, clinicians need to 
consider the pre-test probability of the disease in question, based on the prevalence of the 
disease in symptomatic patients. 
How to Make the Diagnosis of IBS 
The diagnosis of IBS should be made based on four key aspects:  1. Clinical history; 2. 
Physical examination; 3. Minimal laboratory tests; and 4. Colonoscopy or other appropriate 
tests (when clinically indicated). 
1. Clinical History 




Fulfilling diagnostic criteria is mandatory to make the diagnosis of IBS but it is not enough. 
Some organic diseases may also meet these criteria. Among more than 4000 patients with GI 
symptoms attending outpatient clinics 559 met Rome III criteria for IBS, an organic GI disease 
was present in 136 (24.3%), the commonest being Crohn’s disease (n=10; 7.4%).24 The 
prevalence of organic diseases was significantly lower in IBS-C (12.7%) versus IBS-D (32.1%) or 
IBS-M (23.8%; p < .006).24 Incorporating the absence of alarm symptoms into the diagnostic 
criteria reduced the likelihood of organic disease only in IBS-D but, because alarm symptoms 
are so common, more than 60% of patients still have normal investigations (Figure 3). 
 
Figure 3. Diagnostic algorithm for IBS 
In addition to these main symptoms, other GI and non-GI symptoms are also frequently 
present in IBS patients, and the presence of these concomitant symptoms lends further 
support to the diagnosis (see Table).25-28  
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Table. Other gastrointestinal and non- gastrointestinal symptoms are also frequently present 
in IBS patients, and the presence of these concomitant symptoms lends further support to 
the diagnosis. 25, 26 
Other  intestinal 
symptoms related to IBS 
Other digestive symptoms 
frequently  associated to 
IBS 
Extraintestinal symptoms 
associated with IBS 
Mucus in feces Heartburn Fibromyalgia 
Straining Epigastric pain Chronic fatigue syndrome 
Urgency Early satiety Chronic pelvic pain 
Feeling of incomplete 
evacuation 
Postprandial fullness Temporomandibular joint 
disorders 
 Nausea Headache 
  Neck and back pain 
  Muscle aches or soreness 
  Fatigue, tiredness, dizziness 
  Migraine 
  Palpitations, chest pain 
  Hot flushes 
  Sleep problems 
  Decreased sex drive 
  Dyspareunia 
  Increased urinary frequency and 
urgency, nocturia 
  Anxiety, depression 
  Breathing difficulties, asthma, 
cough 
  Pruritus 





Unpredictable bowel pattern (≥3 different stool form types/week) reinforces the 
diagnosis of IBS in the diarrhea subtype;29 it has not been tested in IBS-C or IBS-M. On the 
other hand, increasing the number of consecutive days without a bowel movement is 
associated with IBS-C.30 Abnormal stool frequency (> 3 bowel movements/day and < 3 bowel 
movements/week), abnormal stool form (types 1-2 or 6-7 of the Bristol scale), excessive 
straining during defecation, defecatory urgency, feelings of incomplete evacuation, and mucus 
with bowel movements, although common in IBS, are not specific.  
IBS patients frequently report that symptoms are induced or exacerbated by meals, 
and about 50% with IBS-D complain of postprandial diarrhea.31 Nevertheless, these findings 
are not specific enough to be part of the IBS diagnostic criteria. Other functional digestive 
disorders and non-digestive functional disorders may be present and these reinforce the 
diagnosis of IBS.25, 26 
Absence of alarm symptoms and family risk 
The presence of one or more lower-GI alarm features (a positive family history of 
colorectal cancer (CRC), rectal bleeding, weight loss, or anemia) does not improve the 
performance of IBS diagnostic criteria.6, 32 However, from a clinical point of view, it is 
reasonable to include them in a directed clinical review. In support of this, recent data show 
that the absence of alarm symptoms reduced the likelihood of organic disease in subjects with 
IBS-D symptoms.24 
Alarm features include: Unintended weight loss (> 10% in 3 months); blood in the 
stools not caused (confirmed) by haemorrhoids or anal fissures; nocturnal diarrhea; fever; and 
a family history of CRC (or polyposis syndromes), IBD or celiac disease. 
Consider dyssynergic defecation (in patients with IBS-C) 
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It is important to distinguish dyssynergic defecation (DD) from other subtypes of 
constipation (including IBS-C) because DD has a distinct physiological mechanism and responds 
to different treatments. DD can be suspected based on a clinical history and physical 
examination.33, 34 However, an accurate diagnosis requires tests that are associated with 
additional costs, may be invasive, and which may  not be widely available (see Chapter 14). 
Diet and psychosocial factors 
A dietary history should be performed, with the help of a diary if necessary, with 
special attention paid to the intake of dairy, wheat, caffeine, fruits, vegetables, juices, 
sweetened soft drinks, and chewing gum, since these may exacerbate IBS symptoms or mimic 
IBS symptoms (see Chapter 4). 
A brief psychosocial review should also be performed. Several available tests, including 
the HAD questionnaire and the PHQ12SS somatization score, may be useful (see Chapter 8). 
2. Physical Examination 
The intent of the physical examination is to reassure the patient and to exclude an organic 
basis for the patient’s symptoms. A careful examination should include the anorectum and a 
digital examination with the following goals: 1. Identify anorectal causes of bleeding (mainly 
haemorrhoids and fissures) to avoid unnecessary diagnostic tests (i.e., colonoscopy); 2. 
Evaluate anal strength, (important in patients with IBS-D or IBS-M and incontinence) and 
inappropriate contraction of the puborectalis and/or anal sphincter (in patients with IBS-C), 
and 3: determine whether an abnormal pattern of abdominal wall contraction develops during 
simulated evacuation in patients with IBS-C. 
3. Laboratory Tests 
 In almost every case of abdominal pain and bowel habit abnormalities a CBC and CRP 
should be performed. A systematic review and meta-analysis has shown that CRP and 
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calprotectin determinations are helpful in differentiating IBS from IBD.35 Routine thyroid tests 
are not helpful, but can be checked in the appropriate patient if clinical suspicion is high. 
Serologic tests for celiac disease should be performed in patients with IBS-D and IBS-M who 
fail empiric therapy. Older studies demonstrated a higher prevalence of celiac disease in 
subjects with IBS symptoms than in the general population,36-38 although a large, multicenter 
trial did not confirm this.39 Upper gastrointestinal endoscopy with duodenal biopsies should be 
performed if serologic tests are positive or if clinical suspicion is high; biopsies can also be used 
to identify tropical sprue, which can mimic IBS symptoms.40  
Stool analysis (bacteria, parasites and ova) may be useful if diarrhea is the main 
symptom, especially in developing countries where infectious diarrhea is prevalent.  
As discussed previously, fecal calprotectin may be useful to help distinguish IBS from 
an inflammatory process (mainly in non IBS-C patients younger than 50 years).  Each 
laboratory should identify its own cut off values.41 When borderline values are obtained the 
clinician should repeat the fecal calprotectin before performing colonoscopy (if no other 
indication for colonoscopy exists).42 
A screening colonoscopy is indicated in all patients ≥ 50 years in the absence of 
warning signs (45 years in African-Americans). Colonoscopy is also indicated for: the presence 
of alarm symptoms or signs; a family history of colorectal cancer (according to individual risk: 
patient age, type of symptoms, specific familial background, etc.); watery diarrhea; and > 6-10 
bowel movements/day and/or persistent diarrhea that has failed empiric therapy (consider 
microscopic colitis - mainly in women > 50 years of age). Biopsies of different segments of the 
colon are required.43, 44 
When diarrhea is present, especially if watery, with more than 4-6 bowel movements 
per day and/or associated urgency, bile acid malabsorption and carbohydrate malabsorption 
should be suspected. Given the high prevalence of bile acid malabsorption (BAM) and 
18 
 
increased BA synthesis in patients with IBS-D symptoms an empiric therapeutic trial with a BA 
sequestrant (cholestyramine or colesevelam) is reasonable.45, 46 Scintigraphic evaluation by the 
75SeHCAT test or postprandial C4 (7a-hydroxy-4-cholesten-3-one) serum determination are 
diagnostic options, although neither are widely available.  
Carbohydrate (e.g., lactose, fructose, sorbitol) malabsorption is another frequent cause of 
liquid/watery diarrhea.47, 48 Breath tests are helpful in the diagnosis but if not available a 4-
week trial free of the suspected carbohydrate is recommended to evaluate the clinical 
response.  
KEY POINTS 
The following points highlight notable changes from Rome III: 
• The diagnosis of IBS should be made following several steps, according to the clinical 
diagnostic citeria, but not only based on the criteria. Test indications are more clearly 
specified. 
• The main criteria have been reworded: 
o Related to defecation; and/or 
o Associated with a change in frequency of stool; and/or 
o Associated with a change in form (appearance) of stool 
• Symptoms that cumulatively support the diagnosis of IBS are more clearly explained 
• Indications for tests are included 
• Calprotectin is recommended in IBS non-C (< 50 years of age) 
 
Physiological Features 
IBS is a multifactorial disorder with a complex pathophysiology. There appear to be 
factors which increase the vulnerability to developing IBS and factors that are associated with 
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symptom generation and flares. A unifying theme is that these factors lead to dysregulation of 
the "brain-gut axis" resulting in diverse pathophysiological mechanisms, which appear to 
generate some IBS symptoms. Factors that increase the risk of developing IBS include genetic, 
environmental and psychosocial factors. Factors that trigger the onset or exacerbation of IBS 
symptoms include gastroenteritis, food intolerances, chronic stress, and surgeries. The 
resulting pathophysiologic mechanisms include, but are not limited to, altered GI motility, 
visceral hyperalgesia, increased intestinal permeability and immune activation and altered 
microbiota (Figure 4). Symptom clusters of IBS may arise from several etiologies that can differ 
within subgroups of patients.  
 
Figure 4. Proposed pathophysiology of IBS.  
Genetics  
IBS tends to cluster in familes and patients’ relatives are more likely to report IBS 
symptoms than unrelated controls 49. Twin studies have been used to try to ascertain the 
relative contribution of environment versus genetics but these cohorts were never set up to 
assess IBS and so subject classification is variable and important methodological differences 
have resulted in widely varying heritability estimates from 57%50 in an early small study of 686 
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twins to virtually zero in a much larger study of 4,480 twin pairs51. The Virginia twin study of 
10,699 twins found a much greater concordance for self-reported IBS in monozygotic twins 
(17%) than dizygotic twins (8%)52. However, it also showed having a mother with IBS was a 
stronger predictor than having a dizygotic twin with IBS, suggesting that social learning is a 
more important influence than genes. An alternative approach is to study the association of 
IBS with single nucleotide polymorphisms (SNPs) in candidate genes as has successfully been 
done in Crohn’s disease.  A recent genome wide association study (GWAS) using >11,326 
Swedish twins identified the previously unrecognised association of IBS with two genes 
KDELR2 (KDEL endoplasmic reticulum protein retentionreceptor 2) and GRID2IP (glutamate 
receptor, ionotropic, delta 2 (Grid2) interacting protein) suggesting new avenues for 
research.53  Previous candidate gene studies have typically been much smaller and rarely 
replicated. Since the strongest stimulus to develop IBS is an episode of gastroenteritis54 there 
have been several attempts to identify SNPs which predicted the development of post-
infective IBS (PI-IBS). Studies of individuals infected in the Walkerton outbreak of enteric 
infection in 2007 suggested genes related to gut permeability (Cadherin-1, CDH1), immune 
response (Interleukin-6 (IL-6)) and response to bacterial DNA (Toll-like receptor 9 (TLR-9)), but 
this study was underpowered and has yet to be validated in a larger cohort. Others have 
examined genes controlling the inflammatory response, particularly the key cytokine tumour 
necrosis factor-α (TNFα).  IBS patients were more likely to be heterozygous for the -308 (G/A) 
SNP which predicts high production of TNFα than controls (46% versus 26%)55. Possession of 
both the high producer TNF-α SNP and low producer IL-10 allele (-1082 A) were also more 
prevalent in IBS patients (9%) versus controls (3%).  More recently the G allele of SNP 
rs4263839 in the Crohn’s associated proinflammatory gene TNFSF15 has been demonstrated 
to increase the risk of IBS (odds ratio (OR) =1.37) 56 as has another closely linked SNP in the 
same gene.57 This same study also supported the earlier report linking TNF-α to PI-IBS56.  A 
meta-analysis of 5 studies suggested that the high producing GG genotype of the IL-10 (-1082 
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G/A) SNP reduces the risk of IBS58. Serotonin (5-HT) plays a pivotal role in both brain and gut 
physiology and many studies have examined the 5-HT transporter- linked polymorphic region 
(5-HTTLPR) within the promoter region of the serotonin transporter (SERT) gene SLC6A4. The 
short version (ss) which would be predicted to reduce the amount of SERT and hence increase 
serotonin availability at the synapse has been associated with IBS-D in some59-62 but not all 
studies63, 64. The ss polymorphism reduces SERT function when expressed in transformed 
lymphoblasts although changes in SERT expression in intestinal mucosa in IBS have been 
inconsistent, some finding a decrease65,66 while others did not67, 68. Measuring SERT function in 
platelets is technically easier and several studies have linked impaired platelet SERT to 
symptoms in IBS-D 66 69. Animal studies have shown that the ss allele confers increased anxiety 
and susceptibility to behavioral pathology in response to psychosocial stress 70, however, the 
previously reported gene-environment interaction between the s allele and stressful early life 
events leading to depression71 could not be replicated72. More recently, it has been shown that 
an uncommon functional SNP in the untranslated regions (UTR) of the 5HT3 receptor subtype E 
gene (HTR3E) which alters the response to micro-RNA-510  is linked to IBS-D with an overall OR 
of 5.4 (95% confidence interval (CI) 1.9-15.3). 73  
An alternative approach has been to study SNPs in candidate genes identified from 
gene expression in IBS colonic biopsies.  Studies using a microarray have shown a molecular 
signature which distinguished IBS from healthy controls involving genes controlling the host 
mucosal immune response to microbial pathogens74. The most recent study from this group 
showed a link between genetic tendency to inflammation and colonic transit which suggested 
that these genetic polymorphisms do have a functional effect75. Overall the evidence from 
genetic studies is inconclusive because of inadequate power and poor phenotype definition 
but the recent GWAS studies show that with much larger cohorts progress can be made.  
Stressful Life Events 
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Increasing evidence suggests that chronic, sustained stressors experienced in 
childhood or adulthood are associated with the onset of, and symptom flares, in IBS.76 Early 
adverse life events (EALs) have been found to increase the risk of developing IBS.77, 78 More 
than 40% of patients referred to gastroenterologists for functional gastrointestinal disorders, 
including IBS, are reported to have been physically and/or sexually abused.79, 80 Based on 
animal and human studies, EALs may increase the susceptibility to IBS by increasing visceral 
sensitivity, intestinal permeability, colonic motility, and stress responsiveness.81 Military 
deployment has been shown to be associated with multi-symptom reporting, including 
symptoms of IBS.82, 83 
Gastrointestinal Motor Disturbances 
IBS has long been considered a disorder of disturbed gastrointestinal motility, but 
uniform motility patterns in IBS have been hard to define. Even though exaggerated motility 
induces diarrhea, decreased motility induces constipation, and intestinal “spasms” may cause 
abdominal pain, it has been difficult to relate specific motility findings to the key symptoms of 
IBS, especially abdominal pain.84 No specific colonic motility pattern for IBS has been defined, 
but an increased frequency of high-amplitude propagating contractions (HAPC) and colonic 
propulsive activity have been found in non-constipated IBS patients,85-87 with an association 
between the occurrence of HAPCs and pain episodes.85, 88 Somewhat more consistent has been 
the finding that IBS patients seem to have an exaggerated and prolonged postprandial colonic 
motor response compared with healthy volunteers,85, 89 and a recent large IBS study showed 
an abnormal rectal tone response in IBS patients compared with healthy controls and this was 
unrelated to bowel habit, but associated with the presence of rectal hypersensitivity.90 
Colorectal compliance has also been evaluated in several studies where the general theme 
seems to be a tendency towards reduced compliance, but with no consistent association with 
the predominant bowel subtype.90 Motility disturbances in the GI tract have also been 
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demonstrated indirectly in transit studies, with rather uniform findings with accelerated GI 
transit in IBS with diarrhea and delayed transit in constipation,91, 92 with an association 
between the bowel habit and colonic transit demonstrated using both scintigraphy93 and 
radiopaque markers,94 with approximately 20-30% of patients with FBDs displaying abnormal 
colonic transit.  Abnormal motor function has been demonstrated in other parts of the GI 
tract, suggesting the presence of a generalized GI motor abnormality in some IBS patients84 
(the reader is referred to the section on bloating and distention for a discussion of other 
important mechanisms such as abnormal intestinal gas transit). 
 Visceral Hypersensitivity and Abnormal Peripheral and Central Processing of Sensations  
Enhanced visceral perception, also referred to as visceral hypersensitivity, has been 
demonstrated in IBS and can be due to a greater sensitivity of visceral afferent pathways 
and/or a central amplification of visceral afferent input.95 Factors including hyperalgesia 
(increased pain ratings or lowered pain thresholds to noxious stimuli) and hypervigilance 
(increased attention or bothersomeness to a noxious stimulus) contribute to increased visceral 
perception in IBS. 96-98 
Visceral perception in IBS has been quantified predominantly by pain and discomfort 
thresholds or sensory ratings in response to rectal or colonic distension, usually administered 
by a barostat (computerized distension device). Visceral perception in IBS can be influenced by 
gender,99 bowel habit,100 and cognitive and emotional factors.98, 101 The presence of visceral 
hypersensitivity or hyperalgesia has been found in 8 to 60% of patients.90, 102 
Peripheral mechanisms, such as transient gut inflammation, may enhance visceral 
sensitivity. Release of inflammatory mediators results in peripheral sensitization due to the 
increased firing of primary sensory afferent nerves.103 Animal models have shown that acute 
inflammation alters the neurochemical coding and innervation of the myenteric plexus and 
submucosal nerves,104 changes which have been associated with enhanced sensitivity to 
24 
 
stimulation.105 Recent studies have shown increased numbers of TRPV1 positive neurons in 
rectal biopsies106 and increased staining of the pan-neuronal marker PGP9.5 and brain derived 
neurotrophic factor (BDNF) in enteric nerves in IBS patients107 and these measures correlated 
with severity of pain. 
The importance of central sensitization in enhanced visceral perception in IBS is 
demonstrated by a recent meta-analysis of neuroimaging studies conducted in IBS patients 
with visceral distension. IBS was associated with greater engagement of brain regions involved 
in emotional arousal and endogenous pain modulation and less in areas associated with 
processing visceral afferent information.108 Neuroimaging studies in IBS support the role of the 
CNS in the cognitive, affective and motivational dimensions of the perceptual (including pain) 
experience. More detailed information is in the Central Disorders of GI Pain chapter.  
In addition to abnormalities in visceral perception, there are recent studies that 
demonstrate evidence of somatic hyperalgesia.109 These findings help to explain the relatively 
frequent coexistence of IBS and functional somatic pain syndromes.110 
Autonomic Function and Hypothalamic-pituitary Adrenal (HPA) Axis Function 
An imbalance in the autonomic nervous system (ANS) with increased sympathetic 
and/or decreased vagal tone, which is also seen in chronic stress states, has been found in 
subsets of IBS patients compared with healthy subjects.111 Altered ANS tone has been reported 
in IBS patients at rest112 and during visceral stimulation, including a meal,113 rectosigmoid 
distension,114 sigmoidoscopy,115 and during mental stress.116 Factors that affect ANS tone, 
particularly increased sympathetic tone and/or decreased vagal tone, include male gender,114 
IBS bowel habit subtype,117 more severe disease and a history of anxiety and depression.118  
 The corticotrophin releasing factor (CRF)-HPA axis system provides an integrated 
neurobiologic response to physiologic and psychological stress along with the ANS and 
25 
 
immune system. Activation of central and peripheral CRF signaling pathways has been 
implicated in the alterations in GI motility, permeability, and stress-induced visceral 
hyperalgesia in IBS.119 Studies show evidence of HPA axis dysregulation in IBS, although results 
are varied.81 More studies have demonstrated increased basal levels of cortisol as well as an 
enhanced response to somatic and visceral pain stimuli, psychological stress or hormone 
challenge in IBS patients compared with healthy controls. However, there are a few studies 
that have found normal or blunted responses in IBS.  
Taken together, studies support dysregulation of the ANS and HPA axis systems in IBS. 
These findings give further credence to the clinical observations of stress-sensitive symptoms 
in IBS and provide evidence that stress plays a pathophysiologic role in IBS, via central and 
peripheral mechanisms.  
Post-Infectious IBS 
Postinfectious IBS (PI-IBS) is IBS developing in someone previously free from IBS 
symptoms, immediately after an episode of infectious gastroenteritis characterised by an 
acute illness with   2 of the following clinical features: fever, vomiting, diarrhea and a positive 
stool culture 120.  The proportion of patients developing IBS following intestinal infections 
varies widely from 3.7%-36% and appears to be dependent on the severity of the initial illness. 
The highest figures were reported from the Walkerton outbreak, when the municipal water 
supply was simultaneously contaminated by both Campylobacter jejuni and Escherichia coli 
O147.  Meta-analyses indicate that bacterial gastroenteritis increases the risk of developing IBS 
at 12 months post infection 6.4 fold (95% CI 2.6-15.4), declining to 3.9 fold (3.0-5.0) at 24-36 
months 54. Prognostic studies suggest that more than half last longer than 5 years.121 These and 
other studies show that gastroenteritis is one of the strongest known risk factors for 
developing IBS.122 
Impact of type of infection 
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The type of infection influences the severity of mucosal damage with invasive 
organisms and those producing cytotoxins such as Campylobacter jejuni, Salmonella enteritidis 
and Shigella flexneri being most commonly implicated in PI-IBS.123 124 Viral gastroenteritis, 
though much more common that bacterial gastroenteritis, produces less tissue damage and 
immune activation is restricted to lymphocyte infiltration with no overt ulceration125. Viral 
gastroenteritis appears to be associated with a lower risk of developing PI-IBS compared with 
bacterial infections126. Postviral IBS is usually127 but not always128 transient.  PI-IBS has also 
been reported after giardiasis with an OR of 4.0 (3.5-4.5).129 These patients had lower somatic 
comorbidity than expected in IBS130 supporting the idea that psychological factors may be less 
important in PI-IBS than in unselected IBS as other have reported.131 PI-IBS has also been 
reported after an acute infection with the nematode worm Trichinella britovi.132 
Typical symptoms after PI-IBS  
Six months after gastroenteritis around 25% of patients report looser, more frequent 
stools, but only around 10% also report abdominal pain diagnostic of IBS 123. Typical associated 
symptoms include urgency, bloating, excess mucus and loose frequent stools.  A survey of 840 
cases of C. jejuni enteritis reported 103 cases who developed PI-IBS using the Rome I criteria, 
63% of whom were classified as diarrhoea predominant120. 
The strongest risk factors relate to the type and severity of infection. Thus, prolonged 
initial illness123, weight loss133, rectal bleeding133, and the production of cytotoxin134 give 
relative risks (RR) of 11.5, 1.8, 1.7, and 12.8 respectively. Other risk factors include the nature 
of the host response assessed using rectal mucosal lymphocyte and enterochromaffin (EC) cell 




Several studies have analyzed various aspects of gut, as well as of systemic immune 
function in IBS, and the results differ between studies. However, the majority of studies have 
demonstrated at least some abnormalities in line with low-grade inflammation and/or 
abnormal immune function. 136 Increased innate immune function has been found in 
subpopulations of IBS patients, and the main focus has been on mast cells and monocytes.136 
Increased numbers of mast cells in the gut mucosa of IBS patients have been demonstrated in 
the majority of studies137-139 but there are also studies with no difference140 or even lower 
number of mast cells141 in IBS patients compared with controls. However, of potentially greater 
interest than the actual number of cells are what they produce, and higher levels of mast cell 
mediators, such as tryptase, trypsin and histamine have been documented in biopsy 
supernatants from IBS patients,138, 142, 143 and mediators of colonic mast cells in patients with 
IBS, but not in healthy individuals, excite visceral neurons.142 Mast cells may be distributed 
throughout the mucosa and submucosa, however colonic mast cell infiltration and mediator 
release in close proximity to mucosal innervation (within 5 microns) may contribute to abdominal 
pain perception in IBS patients, possibly.142 Regarding monocytes and macrophages, the 
majority of studies have assessed these indirectly by measuring levels of cytokines primarily 
produced by these cells in blood or mucosa with conflicting results.140, 144, 145 The implication 
that an activated adaptive immune response is involved in the pathogenesis of IBS is 
supported by reports of increased number of T cells in various compartments of the intestinal 
mucosa.139, 146 Moreover, IBS patients seem to have more activated T-cells in blood samples, 
but not altered function or frequency of regulatory T cells 147 Also, B cells in the blood of IBS 
patients seem to have an increased activation level compared with control subjects.148  
Serotonin  
As previously mentioned, changes in SERT expression in intestinal mucosa in IBS have 
been inconsistent65 66 68. Several studies have linked impaired SERT function in platelets to IBS 
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physiology and IBS-D symptoms69 66. The key mediator is likely to be the local release of 
serotonin which has been hard to assess. Measuring serotonin in platelet-depleted plasma 
after a test meal has suggested increased release in PI-IBS and IBS-D149 150 and a decrease in 
IBS-C 149, 151. The levels correlate with sigmoid motility both fasting and postprandially152, but 
the technique is difficult since platelets contain 1000 times the concentration of 5-HT as 
plasma, so any minor activation can confound results. The benefits of 5HT3 receptor 
antagonists and 5HT4 agonists are the best evidence that deranged 5-HT metabolism underlies 
the symptoms.  
Abnormal Intestinal Permeability 
By using oral probe excretion assays, abnormal intestinal permeability has been 
demonstrated in IBS patients, primarily, but not solely, in PI-IBS153, 154 Biopsies have shown 
evidence of  abnormal intestinal integrity and disruption in tight junctions in IBS patients 
relative to controls, although it appears  largely unrelated to IBS subtype.138, 155 Several factors 
may be responsible for the impaired intestinal barrier function seen in IBS patients, including 
food constituents such as gluten, immune abnormalities, and also psychological factors (e.g., 
stress).155-158 
Gut Microbiota 
The GI tract microbiota may have an important role in the onset and maintenance of 
IBS, particularly postinfectious IBS.159 Several studies have already described the microbiota 
composition in IBS patients and although differences from controls have been described, these 
are inconsistent and so far no specific species have consistently been associated with IBS.160 A 
finding that has been seen in several studies is a gut microbial composition enriched with 
Firmicutes together with a reduced abundance of Bacteroidetes in IBS patients compared to 
healthy individuals.161, 162 Moreover, another frequent finding is reduced fecal microbial 
diversity in IBS patients compared to controls or at least in a subset of IBS patients.163 To date, 
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a specific “IBS microbiota” has not yet been defined. The relevance of small intestinal bacterial 
overgrowth (SIBO) in IBS remains to be proven, as initial reports using the lactulose hydrogen 
breath test suggesting an important role for SIBO in IBS,164 have been hard to replicate.165, 166 
Further, by using the gold standard for diagnosing SIBO, i.e. culture of jejunal aspirate, and 
commonly used cut-off levels for small intestinal bacterial counts for diagnosing SIBO, no 
evidence for SIBO in IBS have been detected,165 even though a mild increase of small intestinal 
bacteria has been noted in patients with IBS in two studies.165, 167 However, the relevance for 
IBS symptomatology is still debated and not proven.  
Role of Diet 
One community survey suggested minor differences in diet between IBS patients and 
healthy controls, with IBS patients eating slightly more fat and less carbohydrate 168. A larger 
study found a tendency for higher intake of fruit to be associated with more severe symptoms 
in IBS-D 169. In one large study systematic exclusion diets were shown to benefit 36% of 200 IBS 
patients studied, and importantly, of those who responded, 37% remained well on the diet a 
mean of 15 months later 170. The commonest foods implicated in causing symptoms were 
onions (35%) followed by milk (32%) and wheat (30%). Similar foods were identified in a survey 
of Swedish IBS patients which also reported that beans, fruit and fatty foods aggravated 
symptoms in >20% 171. Patients often believe they are “allergic” to some foods and 
epidemiological studies do suggest a link between respiratory allergy and IBS,172 #830}173 but 
the largest study of 91,237 asthmatics in the UK reported the  lowest risk with an OR  of only 
1.2 (1.0-1.5)174.  Objective testing of reported food allergy by double blind challenge175 only 
confirms this in around 10%176. Atopic individuals with IBS who self-refer because of perceived 
food allergy are more likely to have increased serum IgE and increased mucosa IgE positive 
cells. However, their numbers did not correlate with IBS symptoms175. 
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Initial interest in the role of IgG and particularly the subtype of IgG4 antibodies, which 
can activate mast cells, was stimulated by one uncontrolled report 177 and one randomised 
trial178 from secondary care that antibody-directed diets could improve IBS symptoms.  
However, the commonest antibodies were to wheat and milk, and thus the trial was essentially 
one of wheat and dairy exclusion, which is known to be effective, at least in some IBS patients 
probably because of exclusion of FODMAPs (see below). More recently a large community 
based survey has shown that the incidence of IgG food antibodies is no different in IBS from 
controls when controlled for food intake179. 
Role of Gluten  
Gluten is the part of wheat protein which gives dough its elasticity and traps gas to 
make bread rise, giving it its light texture. Public demand has led to the development over the 
last century of flour with higher gluten content. While true celiac disease is uncommon with an 
incidence of < 1% in those of Northern European descent, many patients with IBS claim benefit 
on a gluten-free diet (GFD), despite not meeting standard criteria for celiac diagnosis.  An early 
study of an open label GFD in IBS-D reported that patients with IBS-D had a higher than normal 
incidence of HLADQ2/8 positivity (39%), and that those that were positive were more likely to 
respond to the GFD, 60% versus just 12% who were HLDQ2/8 negative180. 
Such patients, who do not meet strict criteria for celiac disease but in whom wheat-
induced symptoms have been confirmed using a double blind wheat challenge have been 
reclassified as having non-celiac wheat sensitivity (NCWS). Studies of these patients suggests 
that there are at least 2 subgroups within NCWS, one with features suggestive of occult celiac 
disease (anaemia, duodenal lymphocytosis) and one with allergies to multiple foods and 
duodenal and colonic eosinophilia181.  These conditions must be distinguished from the very 
rare wheat dependent exercise-induced anaphylaxis characterised by urticarial and 
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anaphylactic collapse,182, 183 which has been linked to the presence of IgE to a range of specific 
gliadin subtypes.184 
Gliadin is known to be somewhat resistant to peptic digestion and in animal studies 
has been shown to be toxic to enterocytes, releasing zonulin and increasing permeability 
possibly via binding to the chemokine receptor CXCR3185. A recent placebo-controlled trial in 
IBS patients showed that a GFD decreased stool frequency and  small bowel permeability, an 
effect again more obvious in HLADQ2/8 positive patients157.  The apparent benefit of GFD may 
be due to the low FODMAP content since wheat accounts for around two-thirds of dietary 
fructans and oligofructose in both the United Kingdom186 and the US187. 
Mechanism of FODMAP-induced Symptoms 
Anecdotal clinical experience had long suggested that some patients respond to 
restricting poorly absorbed carbohydrates but it was not until a rigorous chemical approach 188 
identified the key components, which were then given the acronym FODMAPs189 (see text 
box). Such substances escape absorption in the small intestine where the small osmotically 
active ones induce water secretion and accelerate transit delivering large boluses of water and 
rapidly fermentable substrate to colonic bacteria, which respond by producing gas and short 
chain fatty acids. It is believed that the ensuing distension stimulates colonic contractions, and 
in a hypersensitive individual, abdominal pain and frequent defecation.  
Psychological Features  
Psychological disturbance is associated with IBS, especially in patients who seek 
medical care,190  and psychosocial factors affect outcome.191 Regardless of care-seeking status, 
IBS is associated with more psychiatric distress, sleep disturbance, “affective vulnerability” and 
“over-adjustment to the environment”.192 Moreover, in a recently published 12-year 
prospective study, support for a bidirectional interaction between the gut and the brain in 
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patients with IBS was suggested, as anxiety and depression at baseline could predict the 
development of IBS at follow-up, but the presence of IBS at baseline could also predict more 
severe anxiety and depression at follow-up.193 For more detailed information, please see the 
chapter on Psychosocial factors. 
Other Factors  
 Bile acids entering the colon stimulate motility and secretion and may therefore be of 
relevance in IBS patients, especially for bowel habits of patients. In a systematic review bile 
acid malabsorption was found to be a common finding in IBS-D patients and in patients with 
functional diarrhea.45 Recently, increased bile acid synthesis was demonstrated in patients 
with IBS-D, but not in IBS-C,158 and an association between the excretion of unconjugated bile 
acids and the stool characteristics has been seen in IBS, and these effects were independent of 
colonic transit.194 Moreover, by using the 75SeHCAT test, another recent study in a mixed group 
of IBS patients found an abnormal test (SeHCAT retention <10% on day 7) in 18% of IBS 
patients, and abnormal tests were predominantly seen in non-constipated IBS and associated 






 The type and severity of symptoms (digestive and non-digestive) and the nature of 
associated psychosocial issues determine treatment. In addition to allaying fear of serious 
disease, the physician should assess the impact of IBS symptoms on patient's quality of life and 
level of daily functioning, taking into account the patient's personality, recent life stress, 
anxiety and depression. A patient's reaction to their IBS symptoms may be more important 
than the symptoms themselves, and psychological factors may alter symptom perception and 
lead to multiple consultations, unjustified and hazardous investigations, and even unneeded 
surgery 196 The cornerstone for any effective therapy is a strong physician-patient relationship, 
which can improve IBS symptoms 197 and reduce health care utilization198. 
Figure 5.  Treatment of IBS   
Dietary and Lifestyle Modification  
While the benefits of exercise to general well-being as well as co-morbid conditions 
commonly encountered in IBS patients including psychological distress and fibromyalgia 199 has 
been well established only recently has moderate to strenuous exercise been shown to 
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improve IBS symptoms 200.  Therefore, it seems logical for providers to incorporate exercise 
into the treatment of most IBS patients199, 200.   
Dietary recommendations in IBS have moved far beyond just fiber supplementation 
and avoidance of common “culprit” foods such as fatty/greasy foods or those that contain 
lactose201. While such recommendations can still be of benefit to selected individuals, it is clear 
that they are not a panacea for most IBS patients.  
Dietary fiber supplementation remains a cornerstone of IBS management although its 
optimal use in clinical practice can be more nuanced than is often appreciated202Ford, 2014 #454}. A 
recent systematic review and meta-analysis identified 12 trials comparing fiber with control 
and found a only marginal difference in the proportion of IBS patients with persistent 
symptoms after any type of fiber vs. the control intervention (52% vs. 57%, RR 0.87; 95% CI 
0.76 to 1.00, NNT = 11)135 When only the 7 higher quality studies were analyzed, there was no 
treatment benefit for fiber vs. control (RR of persistent symptoms = 0.90, 95% CI = 0.75 to 
1.08).  Subgroup analysis suggested that benefits for IBS symptoms were confined to soluble 
(psyllium/ispaghula husk) as opposed to insoluble (bran) fiber. These findings were more 
recently confirmed by a comparative effectiveness trial which assessed the benefits of 
psyllium, bran or rice flour placebo in IBS patients203. Thus, when fiber is recommended for IBS, 
soluble supplements such as psyllium or ispaghula are best supported by the evidence. Fiber 
should be started at a modest dose and slowly increased over the course of several weeks to a 
target of 20-30 grams of total dietary and supplemental fiber per day. Certain forms of fiber 
and particularly bran, which contain large amount of non-absorbed, highly fermentable 
fructans, can exacerbate problems with abdominal distension, flatulence, constipation and 
diarrhea in IBS patients204.  
Other dietary interventions, such as gluten-free and low fermentable oligo-, di-, 
monosaccharides and polyols (FODMAP) diets, have become increasingly popular as primary or 
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adjunctive treatment strategies for IBS.135  Recent data from clinical trials suggests that a 
gluten free diet can lead to significant symptom improvement in a subset of IBS sufferers205. In 
a randomized controlled 4-week trial involving 45 patients with IBS-D without celiac disease, a 
gluten-free diet reduced bowel frequency and decreased small bowel permeability as 
measured by the lactulose:mannitol ratio.  IBS-D patients who were HLA-DQ2/8-positive were 
more likely to be responders than those who did not have the gene associated with celiac 
disease 157.  Further evidence supporting a gluten-free diet in IBS patients is found in a double-
blind, randomized, placebo-controlled rechallenge trial.  In this study reintroduction of gluten 
in a blinded manner in IBS patients who had response to a gluten-free diet was associated with 
an increase of symptoms in 68% of IBS patients compared with 40% of those IBS patients who 
remained on a gluten free diet.  Individual symptoms such as bloating, abdominal pain, and 
tiredness were more likely to increase in patients receiving gluten than those who remained 
on a gluten-free diet205. Adding a gluten-free diet to IBS patients already on a low FODMAP 
diet does not offer additional benefit206.  
Whether the clinical benefits observed are the consequence of gluten 157, other wheat 
proteins181, highly fermentable short chain carbohydrates 206, or the nocebo effect 204 remain 
to be elucidated. It is clear that non-celiac wheat intolerance is not a single condition but 
rather, represents the symptom experience arising from one or more pathophysiological 
pathways. If one chooses to recommend a gluten-free diet to patients with IBS symptoms, it is 
critical to appropriately screen for celiac disease before instituting a gluten-free diet.  
There is accumulating evidence from retrospective and prospective controlled trials 
that dietary FODMAP restriction is associated with reduced fermentation and significant 
symptom improvement in a subset of IBS sufferers 207 208, 209. It appears that restriction of both 
fructose and fructans is necessary to achieve the full clinical benefits of this dietary 
intervention 210. In a randomized, controlled, single-blind cross-over trial, 30 IBS patients who 
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had not previously tried dietary manipulation reported significant reduction in overall 
gastrointestinal symptom scores compared with those on a standard Austrialian diet (22.8 vs. 
44.9; range 0-100, p<0.001).  Patients of all IBS subtypes had greater satisfaction with stool 
consistency while on the low-FODMAP diet, but IBS-D (n=10) was the only subtype with 
improvement in altered stool frequency 209. 
Response to FODMAP restriction is usually assessed after 4-6 weeks. Responders then 
engage in a structured reintroduction of FODMAP-containing foods which allows the individual 
to tailor his/her diet. The complexity of the low FODMAP diet and the need for a structured 
food reintroduction phase emphasizes the critical role of a properly trained dietician in the 
team caring for IBS patients.  Other groups have assessed empiric food elimination diets 211 as 
well as the potential role of food additives (e.g., histamine and salicylates) in the pathogenesis 
of IBS symptoms 212.  
Peripherally Acting Agents 
Laxatives  
Though commonly recommended to patients with IBS-C because of their wide 
availability, low costs and perceived safety, there are few clinical trials in patients with IBS-C. A 
randomized, placebo controlled trial conducted in adults with IBS-C confirmed the benefits of 
PEG (13.8-41.4 grams/day for 4 weeks) for stool frequency, stool consistency, and straining  
but not for abdominal symptoms such as abdominal pain or bloating 213. Overall, PEG was well 
tolerated in these studies. The most commonly reported adverse events were abdominal pain 
and diarrhea, both of which occurred in less than 5% of patients. A second randomized, 
controlled trial in adolescents reported similar results214.  
Prosecretory Agents (Secretagogues) 
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 Current prosecretory drugs exert their effects via chloride channels located on the 
apical surface of enterocytes.  Further details can be found in Chapter 5. Lubiprostone is a 
luminally-acting prostone which selectively activates type 2 chloride channels (ClC-2).215,216 
Active secretion of chloride ions leads to secondary passive paracellular movement of sodium 
and water.  The resultant luminal distension stimulates gastrointestinal (GI) tract motility with 
attendant effects on intestinal and colonic transit).215 Lubiprostone may also stimulate smooth 
muscle contraction through prostaglandin E1 receptors, suggesting a direct effect on GI 
motility217. Currently lubiprostone has been approved for the treatment of adult women with 
IBS-C (8 μg twice daily) in a number of continents and countries.  In a large, placebo-controlled, 
randomized study involved over 1,100 IBS-C patients, lubiprostone (8 ug twice daily) resulted 
in significantly higher overall response compared with placebo (17.9% vs. 10.1%, P=0.001) over 
12 weeks of treatment218. A subsequent extension study followed IBS-C patients taking 
lubiprostone for up to 52 weeks. The most common adverse effects were nausea (8% v. 4% 
placebo) and diarrhea (6% v. 4% placebo)219. Lubiprostone should be dosed with food to 
reduce the incidence of nausea. 
Linaclotide is a 14 amino acid peptide that acts on the guanylate cyclase C (GC-C) 
receptor located on the luminal surface of intestinal epithelial cells. GC-C receptor activation 
leads to the production of intracellular cGMP and subsequent activation of CFTR with resultant 
chloride secretion; the increase in extracellular (basolateral) cGMP increases the threshold for 
colonic nociception and is believed to thereby reduce sensation of pain215. Linaclotide is 
approved in the US, Canada, Mexico, Switzerland and the EU for adults with IBS-C at a dose of 
290 mcg daily.  In 2 large phase III trials linaclotide was found to be more effective than 
placebo at improving bowel and abdominal symptoms in IBS-C patients 220-222.  A 6 month, 
double-blind, placebo-controlled phase III trial utilized a combined end point which required 
improvement of ≥ 30% from baseline in average daily worst abdominal pain score as well as an 
increase of ≥ 1 complete spontaneous bowel movement (CSBM) from baseline for ≥ 6/12 
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weeks.  Linaclotide resulted in a response rate of 33.7% vs. 13.9 % for placebo-treated patients 
(P < 0.0001, number needed to treat (NNT) = 5.1, 95 % CI: 3.9, 7.1). Diarrhea was the most 
commonly reported adverse event with linaclotide (19.7% vs 2.5% placebo). Other than 
diarrhea, the incidence of adverse events was similar between treatment groups.  Linaclotide 
should be taken on an empty stomach at least 30 minutes prior to the first meal of the day.  
 A second GC-C agonist, plecanatide, is currently in development.  In a dose ranging trial 
plecanatide improved abdominal pain and bowel habits in IBS-C at 3.0 and 9.0 mg dosing (41.9% 
and 40%, respectively, compared to 24.7% for placebo for the FDA Endpoint for IBS-C). 223 
Bile Acid Modulation 
Modulation of bile acids in the GI tract has recently gained interest as a treatment of 
functional bowel disorders.  Bile acids such as chenodeoxycholic acid (CDCA) elicit dose 
dependent increases in stool frequency224, 225 and a double-blind, placebo-controlled study 
found that sodium CDCA accelerated colonic transit and improved bowel function in 36 
females with IBS-C 226. More than 40% of patients treated with CDCA experienced lower 
abdominal cramping/pain (P = .01). Further studies are required and CDCA has yet to receive 
approval. 
A recent systematic review found bile acid malabsorption to be common in IBS-D type 
patients 45.  In this study 10% of patients had severe bile acid malabsorption as determined by 
SeHCAT while 32% had moderate bile acid malabsorption.  The more severe the bile acid 
malabsorption the more likely patients were to respond to a bile acid sequestrant.  In a 
pharmacodynamics study of 24 IBS-D patients, colesevelam, a bile acid sequestrant, delayed 
emptying of the ascending colon compared with placebo, and was associated with greater 
ease of stool passage (p = 0.048) and somewhat firmer stool consistency (p = 0.12) 227. Several 




Loperamide is a synthetic peripheral mu-opioid receptor agonist which decreases 
colonic transit, and increases water and ion absorption.  In a small placebo-controlled study of 
25 IBS-D patients (21 completed), Lavo and colleagues found loperamide improved stool 
consistency, pain, urgency and subjective overall response 228. In another study 229, loperamide 
improved stool consistency, reduced bowel frequency, and reduced intensity of pain though it 
increased nightly abdominal pain.  Finally, in a small group of IBS-M patients (n=21), Hovdenak 
230 found improvement in stool frequency and consistency as well as fewer painful days during 
loperamide treatment.  Clinically, loperamide is used to reduce rectal urgency and frequency.  
Constipation may develop and therefore dose titration may be necessary.   
Systemically Acting Agents 
Antispasmodics 
Antispasmodics are either anticholinergic or direct smooth muscle relaxants that 
reduce contractions within the gastrointestinal tract.  A meta-analysis involving 12 different 
anti-spasmodics found a RR of persistent symptoms after treatment of 0.68 (CI 95% 0.57-0.81) 
with a NNT to prevent symptoms of 5 (CI 4-9)202.  Likewise, enteric-coated peppermint oil also 
has anti-spasmodic properties and has been extensively studied in IBS.  A recent meta-analysis 
found peppermint oil treatment to be significantly superior to placebo for global improvement 
of IBS symptoms (RR 2.23; 95% CI 1.78-2.81) and improvement in abdominal pain (RR 2.14; 
95% CI 1.64-2.79). The most commonly reported adverse event was heartburn 231.  
Antidepressants 
Tricyclic antidepressant agents (TCAs) (e.g., amitriptyline, desipramine) are frequently 
used to treat patients with IBS, particularly those with IBS-D because of the potential for the 
anti-cholinergic effects of TCAs to cause constipation.  In general TCAs appear to be effective in 
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treating IBS symptoms (RR of remaining symptomatic 0.66 (95% CI 0.56-0.79), NNT of 4 (95% CI 
3 to 6)), however, only one clinical trial232 included only IBS-D patients.  In this study, which 
included 52 patients with IBS-D, after 2 months 10 mg amitriptyline resulted in reduction in 
the incidence of loose stool and feeling of incomplete defecation as well as complete response 
(defined as loss of all symptoms) in 68% of patients compared with 28% complete responders 
with placebo.  At this dose of amitriptyline side effects were similar between the groups.  
A recent systematic review and meta-analysis summarized the efficacy data for 
selective serotonin reuptake inhibitors. Seven trials were included which showed a RR of 
remaining symptomatic of 0.68 (95% CI 0.51-91, NNT = 4 (95% CI 2.5-20).202 There are few 
studies which have evaluated selective norepinephrine reuptake inhibitors in IBS. At present, it 
is difficult to draw any conclusions regarding efficacy based upon the limited available data. 
Further studies are clearly needed.  
The most common adverse events reported with antidepressants were drowsiness and 
dry mouth, particularly in patients receiving TCAs. 
Prokinetic Agents 
Prucalopride is a selective 5-HT4 receptor agonist that has been found to be effective 
in the treatment of patients with chronic constipation but, to date, has not been subjected to 
randomized, placebo controlled trials in IBS-C patents.  
5-HT3 Antagonists  
Antagonism of 5-HT3 receptors, which are found on enteric motor and sensory neurons 
and in central locations such as the vomiting center, has been shown to reduce visceral pain, 
colonic transit and small intestinal secretion. Alosetron, a highly selective 5-HT3 antagonist, 
has been shown to relax the colon, and increase thresholds for visceral sensation in IBS 
patients and decrease intestinal transit, particularly in women233.  Alosetron has been shown 
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to be effective in relieving pain, reducing stool frequency and rectal urgency in women with 
IBS-D.202, 215, Alosetron was initially approved by the FDA at a dose of 1 mg twice daily for the 
treatment of women with IBS. However, due to safety concerns (ischemic colitis and 
complications of constipation) it was removed from the market and then subsequently 
reintroduced under an ongoing risk management plan.  Currently, alosetron is approved only 
in the U.S. for women with severe IBS-D beginning at a lower dose (0.5 mg twice daily).  Since 
its reintroduction, the incidence rates have been 4 and 2 cases per 1000 patients for ischemic 
colitis and complications of constipation, respectively (i.e., 0.95 and 0.36 cases per 1000 
patient-years, respectively)234.  To date one study has evaluated the effects of the lower dose 
of alosetron (0.5 mg qd) in women with severe IBS-D.  In this study 0.5 mg q.d. of alosetron 
resulted in significant improvements in symptoms and health-related quality of life, restriction 
of daily activities and treatment satisfaction over placebo 235. Recent studies have found 
ramosetron and ondansetron to be effective in the treatment of IBS-D.236, 237  
Microbiome and Immune-modulators 
Probiotics 
Probiotics may benefit IBS patients through multiple mechanisms including 
modification of gut bacterial communities, mucosal immune function, mucosal barrier 
function, function of neuroendocrine cells, and fermentation238. Bifidobacterium infantis 
35624 led to significant improvements in abdominal pain/discomfort, bloating/distention, 
and/or bowel movement difficulty compared with placebo (P<0.05) in two randomized, 
placebo-controlled trials conducted in IBS patients239 240. A fermented dairy product containing 
Bifidobacterium lactis DN-173 010 also resulted in reduced symptomatology and significant 
gastrointestinal transit improvement in patients with IBS-C241. 
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 In a recent meta-analysis which included 43 clinical trials, the RR of IBS symptoms 
persisting was 0.79 (95% CI 0.70-0.89). Probiotics were found to offer benefits to global IBS 
symptoms, pain, bloating and flatulence242.  Given the data to date, it is reasonable to 
speculate that some single and multi-strain probiotics will offer clinical benefits to patients 
with IBS, however, adequately powered, methodologically rigorous, randomized, controlled 
trials will be needed to clarify the appropriate type, dose and duration.   
Antibiotics 
Several antibiotics have been studied for the treatment of IBS. However, the best 
studied antibiotic is rifaximin, a non-absorbable antibiotic, which is available in the U.S. and 
several other countries.  In two large clinical trials, 2 weeks of treatment with rifaximin 550 mg 
three times daily in patients with non-constipated IBS resulted in significantly more patients 
reporting adequate relief of global IBS symptoms (40.8% vs. 31.2%, P=0.01) and bloating 
(39.5% vs. 28.7%, P=0.005)243 during the first 4-weeks of follow-up. Improvement in symptoms 
persisted for the 10 weeks followup period.  A meta-analysis that included five clinical trials 
found rifaximin to be more efficacious than placebo for global IBS symptom improvement 
(OR=1.57; 95% CI=1.22, 2.01; therapeutic gain=9.8%; NNT = 10.2), with mild heterogeneity 
(P=0.25, I(2)=26%)244.   Adverse events with rifaximin were similar to placebo. Repeat 
treatment with rifaximin appears to offer similar efficacy to an initial course of therapy.245 
Mast Cell Stabilizers 
Disodium cromoglycate reduces the release of mast cell mediators such as histamine, 
leukotrienes and cytokines such as TNF-alpha.  In a study of 120 IBS-D patients (55% had 
concomitant food intolerance assessed by skin prick test) with a positive reaction to at least 
one food, an exclusion diet in association with disodium cromoglycate 250 mg q.i.d. for four 
months provided improvement in symptoms compared with an exclusion diet alone246. 
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Ketotifen, another mast cell stabilizer, has been shown to prevent mucosal mast cell 
stimulation induced by cholecystokinin and increased the threshold pressure for induction of 
discomfort by rectal balloon distension in 30 IBS patients with visceral hypersensitivity but not 
in normosensitive IBS patients141. In this study, ketotifen significantly decreased abdominal 
pain and other IBS symptoms and improved quality of life.   
5-Aminosalicylic Acid 
Early small trials suggested possible benefits of mesalamine for IBS247-249.  More recent 
studies in post-infectious IBS-D and two larger phase 2 trials failed to show significant efficacy 
250, 251.  
Other Potential Treatments 
Medical foods are a new category of treatments defined by the US Food and Drug 
Administration as “a food…formulated to be consumed or administered enterally under the 
supervision of a physician and which is intended for the specific dietary management of a 
disease or condition for which distinctive nutritional requirements, based on recognized 
scientific principles, are established by medical evaluation.” Serum-derived bovine 
immunoglobulin isolate offers a potentially unique treatment option but requires evaluation in 
rigorous, appropriately powered clinical trials.252, 253   
Fecal microbial transplantation for IBS has been reported in case reports and small 
uncontrolled series. Preliminary reports appear promising but the efficacy and safety of FMT 
requires validation in randomized, controlled trials254. 
Complementary & Alternative Medicine (CAM) 
Complementary and alternative medicine therapies are growing increasingly popular 
amongst IBS patients for a number of reasons (cost, ease of use, perceived safety).  Survey 
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studies demonstrated that one-third to one-half of patients with functional GI disorders or IBS 
use CAM therapies 255, 256. 
Herbal Therapies 
 One of the most extensively studied herbal therapies for IBS is “Tong xie yao fang 
(TXYF)”. A systematic review of 12 randomized trials which included over 1000 IBS patients 
found that TXYF was more effective than control treatments (RR of 1.35, 95% CI 1.21–1.50, p 
<0.05)257. Unfortunately, most of the studies were of poor quality undermining any conclusions 
that can be drawn from this analysis. 
A recent high quality, randomized, controlled trial found that St John’s Wort was less 
effective than placebo for IBS symptoms providing a vivid reminder that supplements 
perceived to be “safe” are not necessarily effective258. 
Acupuncture 
Randomized controlled trials have consistently failed to show benefit of acupuncture 
compared with sham acupuncture259.  However, sham acupuncture appears to be more 
effective than no treatment260. 
Behavioral Therapies 
 The efficacy of psychological/behavioral therapies including cognitive behavioral 
therapy (CBT) or hypnotherapy is discussed in detail in Chapter 8 but appears to be agnostic to 
IBS subgroup. A recent systematic review and meta-analysis identified 11 randomized, 
controlled studies  which defined IBS by the Rome criteria (I-III) and found that the majority of 
studies reported statistically significant improvements for the primary study endpoint with CBT 
(6 studies) or hypnotherapy (5 studies). These trials tended to enroll all subgroups of IBS 




C2. FUNCTIONAL CONSTIPATION 
Definition 
Functional constipation (FC) is a functional bowel disorder in which symptoms of 
difficult, infrequent or incomplete defecation predominate. Patients with FC should not meet 
IBS criteria, although abdominal pain and/or bloating may be present but are not predominant 
symptoms.  
Symptom onset should occur at least 6 months prior to diagnosis, and symptoms 
should be present during the last 3 months.   
 
* It should be noted that patients with FC, as well as those with IBS-C, have constipation of 
functional origin and these disorders are considered a continuous spectrum.   
 
KEY POINTS 
 The following points highlight notable changes from Rome III: 
• “Persistently” has been deleted (chronicity is part of the general FBDs definition). 
• It is specified that abdominal pain and/or bloating may be present but are not 
predominant (i.e., the patient does not meet criteria for IBS). 
• “Criteria present for the last 3 months and onset at least 6 months prior to diagnosis” 
has been replaced with “Symptom onset should occur at least 6 months prior to 
diagnosis and symptoms should be present during the last 3 months”. 
• It is noted that when referring to patients with constipation of functional origin both FC 





Few studies have evaluated the incidence of chronic constipation of functional origin 
in adults. Most epidemiologic studies have focused on patients with chronic constipation who 
may or may not meet strict criteria for FC. One study reported onset rates of 40/1,000 person 
years when patients were resurveyed a median of 14.7 months after the initial survey.262 Using 
modified Rome II criteria a community study identified a 12-year cumulative incidence of 
constipation of 17.4%.263 
Accurately measuring the prevalence of constipation is problematic because 
researchers have used a variety of definitions and questionnaires, while patients’ self-
reporting of symptoms is subjective, influenced by societal customs, and correlates poorly with 
stool frequency. In adults the mean prevalence rate of chronic constipation is approximately 
14%, with rates that range from 1.9 to 40.1%.264 A large postal survey study of Australian 
women (41,724) identified self-reported prevalence rates of constipation of 14.1% in young 
women (ages 18-23), 26.6% in middle-aged women (ages 45-50), and 27% in older women 
(ages 70-75).265 The prevalence rate of post-infectious FC was 127 / 100,000 patient years 
during an eight-year period; this was seven times higher in women compared with men (480 
versus 67 / 100,000 patient years).126 Self-report rates of constipation are generally higher 
compared with use of Rome criteria. Risk factors for FC include female gender, reduced caloric 
intake, and increasing age.266, 267 
The natural history of FC is unclear. One study found that 89% of adults were still 
symptomatic when surveyed 12-20 months after the initial diagnosis.262 However, larger 
population studies reported that symptoms of FC resolved in 77.8% of patients (n = 1365) over 
a 12-year follow-up period,15 and that only 3% of patients (n = 2835) had persistent symptoms 





• Evaluation of symptoms should ideally be done when off of laxatives and medications 
and supplements known to cause constipation. 
 
Diagnosis of FC  
  
Constipation can be established by both subjective and measurable variables: infrequent 
bowel movements, hard stools, excessive straining, feelings of incomplete evacuation, daily 
stool weight <35 g/day, prolonged colonic transit, or evidence of outlet obstruction. None of 
these individual variables alone is ideal to define constipation, and the combination of 
C2.  Functional Constipation 
 
Diagnostic criteria* 
1. Must include two or more of the following:  
a. Straining during at least ¼ (25%) of defecations; 
b. Lumpy or hard stools (Bristol Stool Form Scale 1-2) at least ¼ (25%) of 
defecations; 
c. Sensation of incomplete evacuation at least ¼ (25%) of defecations; 
d. Sensation of anorectal obstruction/blockage at least ¼ (25%) of defecations; 
e. Manual maneuvers to facilitate at least ¼ (25%) of defecations (e.g., digital 
evacuation, support of the pelvic floor);  
f. Fewer than three SBM per week. 
2. Loose stools are rarely present without the use of laxatives 
3. Insufficient criteria for irritable bowel syndrome 




symptoms and quantifiable measures – when needed – seems to be the most useful approach. 
Rome IV FC diagnostic criteria has maintained the 25% (1/4) rule for all six features because it 
is easy to remember and useful in clinical practice; however, figures have been revised based 
on surveys of the U.S. population to identify a symptom as abnormal only if it occurs more 
often than the 90th percentile for the population (see spefic figures for each FC symptom in the 
appendix of this chapter). When these criteria are used in countries where the frequencies of 
these symptoms are known to differ from Western Europe and North America, different 
frequency thresholds may be substituted based on the 90th percentile for that population. 
Colonic transit time can be estimated by evaluating stool form using the Bristol Stool Form 
Scale – stool forms 1 & 2 are associated with slower transit, while stool forms 6 & 7 are 
associated with more rapid transit.19 
A survey of US adults that evaluated patient perspectives of chronic constipation 
showed that the most frequent symptoms were: straining (79%), hard stools (71%), abdominal 
discomfort (62%), bloating (57%), infrequent bowel movements (57%) and feelings of 
incomplete evacuation after a bowel movement (54%).269 Thus, the diagnosis of FC needs to be 
established according to the diagnostic criteria but also in conjunction with the patient’s 
opinion.  This evaluation should be performed, if possible, while the patient is not taking 
laxatives. 
In contrast to the Rome III classification, the last AGA technical review did not use the 
term “functional constipation” because a subset of patients with symptom criteria for FC have 
slow colonic transit.270 Importantly, the AGA and Rome III criteria both emphasize the need to 
identify defecatory disorders.202 It is the opinion of this committee that all cases with no 
evidence of structural or metabolic abnormalities to explain the symptoms should be 
considered under the umbrella of FC (mainly for epidemiological studies, where it is not easy 
to differentiate among different types of chronic constipation). We acknowledge that a 
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diagnosis of slow transit constipation or defecatory disorders requires diagnostic tests (see 
below), which may alter treatment strategies. 
Mechanical obstruction, medications, and systemic illnesses can cause constipation, 
and these causes of secondary constipation must be excluded, especially in patients presenting 
with new onset constipation. Most often, however, constipation is caused by disordered 
function of the colon or rectum. Chronic constipation can be divided into three broad 
categories: normal-transit constipation, slow-transit constipation, and defecatory or rectal 
evacuation disorders (Figure 6).  
Diagnosis of FC 
The diagnosis of FC should be made uing five consecutive steps:  1. Clinical history; 2. 
Physical examination; 3. Minimal laboratory tests; 4; Colonoscopy or other tests (in specific 
cases where available); 5. Specific tests to evaluate constipation pathophysiology (when 
needed and if available). 
1. Clinical History 
Main symptoms: (“Clinical diagnostic criteria”) 
It is important to determine what the patient means when reporting constipation. A 
detailed history should include the duration of symptoms, frequency of bowel movements, 
and associated symptoms such as abdominal pain, bloating or distention should be obtained. 
The history should also include an assessment of stool consistency, stool size, and degree of 
straining during defecation. The presence of warning symptoms or signs, such as unintentional 
weight loss, rectal bleeding, change in stool caliber, severe abdominal pain, and a family 
history of colon cancer should be elicited. A long duration of symptoms that have been 
refractory to conservative measures is suggestive of a functional colorectal disorder. By 
contrast, the new onset of constipation may indicate a structural disease.271 
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Clinical trials have used complete spontaneous bowel movements (CSBM) as an endpoint; 
however, its utility in the diagnosis of FC in clinical practice is unclear.   
Absence of alarm symptoms and family risk 
Specific descriptors of alarm features include: unintentional weight loss (> 10% in 3 
months); blood in the stools not caused (confirmed) by hemorrhoids or anal fissures; fever; 
and a family history of CRC (or familial polyposis syndromes).  
It is important to distinguish dyssynergic defecation (DD) from other subtypes of 
constipation because DD has a distinct pathophysiological mechanism and responds to specific 
treatments. However, the diagnosis currently depends on tests which carry some costs and 
risks, and which may not be widely available. However, DD can be suspected by questionnaire 
and physical examination.33, 34 
2. Physical Examination 
The general physical examination should exclude major central nervous system 
disorders, especially spinal lesions. The abdomen should be examined for distention, hard 
stoolin a palpable colon, or an inflammatory or neoplastic mass. The rectal examination is 
paramount in evaluating a patient with constipation. Painful perianal conditions and rectal 
mucosal disease should be excluded, and defecatory function should be evaluated. The 
perineum should be observed both at rest and after the patient strains as if to have a bowel 
movement.  A digital rectal examination should be performed to evaluate the patient for the 
presence of a fecal impaction, anal stricture, and rectal mass. It is also crucial to evaluate 
contraction of the puborectalis and/or anal sphincter during digital examination.  
3. Laboratory Tests 
TSH (thyroid stimulating hormone) and serum calcium should be performed when 
clinically indicated (e.g., suspected hypothyroidism or diseases inducing hypercalcaemia). 
4. Indications for colonoscopy: 
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All patients aged > 50 years (> 45 in African-Americans (or Blacks)) should have a 
screening colonoscopy. The presence of alarm symptoms (unintentional weight loss, 
hematochezia, anemia) or family history of colorectal cancer (according to individual risk: 
patient age, type of symptoms, specific familial background, etc.) should prompt earlier 
intervention. 
5. Specific Tests to Evaluate Constipation Pathophysiology 
The chronicity, severity and nature of symptoms may indicate the need for specialized 
tests. For example, straining with soft stools and manual maneuvers to assist defecation 
suggest anorectal dysfunction, which can be identified by anorectal manometry.270, 272 An 
estimate of transit time can be obtained from the Bristol Stool Form Scale.19 
 Testing for slow colonic transit and/or DD is neither required nor justified in all 
patients. Moreover, most physicians do not have the ability to perform these evaluations. 
Patients who do not respond to reasonable trials of empiric therapy (e.g. fiber and/or osmotic 
laxatives; see below) should undergo diagnostic evaluation to identify physiological subgroups. 
Measurement of Colon Transit  
 Using radiopaque markers, measurement of whole gut transit time (primarily colon 
transit) is inexpensive, simple and safe.273, 274 A radioisotope technique involves less radiation 
than x-ray studies and may provide more information,275  although it is available in very few 
centers.  
Additional Studies 
To confirm DD, anorectal manometry and balloon expulsion testing may help.276 
Defecography may detect anatomical etiologies, such as intussusception and rectocele with 
stool retention. Defecography also identifies the failure to decrease the anorectal angle with 
straining and abnormal pelvic floor descent, features that are typical of dyssynergic 
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defecation.277 Electromyography and pudendal nerve latency testing are adjunctive techniques 
(See Anorectal Disorders).  
 
Pathophysiology 
Etiology   
Recent meta-analyses show chronic constipation major risk factors to be female 
gender, increasing age and lower socioeconomic status 264 278. The strongest risk was female 
gender with an OD of 2.22; 95 % CI: 1.87 – 2.62. Before puberty the incidence of constipation 





Figure 6. Pathophysiology of FC 
Genetics 
Several studies suggest constipation shows familial clustering281, 282 Moving from 
familial clustering to finding a genetic association is rendered more difficult when the 
phenotype is poorly characterized or there are multiple mechanisms leading to the same 
phenotype as there are with constipation. These mechanisms include diet, microbiota, 
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absorption, secretion and motility as well as behavior and beliefs. The association of 
Hirschsprung’s disease, a cause of constipation not of functional origin, with mutations in the 
RET gene is well recognised 283.  Studies of familial slow transit constipation found no 
mutations in the RET proto-oncogene 284or neurturin (NRTN) 285. Several SNP associations with 
FC have been reported including the bile acid receptor TGR5 SNP rs11554825,286 thought to be 
important in mediating bile acid related peristalsis.  More recently the loss of function NaV1.5 
channelopathy, found in 2% of IBS patients, has been associated with constipation287. A recent 
meta-analysis suggests that the L-variant of the 5HTTLPR is associated with IBS-C in Asian 
populations but not in Caucasian subjects288. Due to the similarities of FC with IBS-C, it is 
plausible to hypothesize similar findingns in non-IBS constipatied patients. 
Onset of Constipation and Life Style Factors 
Constipation often begins in childhood but unfortunately there are few studies in 
children (see pediatric section).  Risk factors appear similar to adults possibly because diet and 
behavioral habits are established early in life. Studies of younger children (3-5 years) from 
Hong Kong show constipation in around one-third with lower fiber intake being a risk factor289 
and fluid intake > 800 ml and a preference for fruit and vegetables reducing the risk290.  Studies 
in Korea291 and the USA reported constipation in around 1 in 10 schoolchildren292. Children’s 
parents felt that poor diet and refraining from using the school toilet was important280.  
 The marked diurnal variation in colonic motility with peak activity on awakening and 
after large meals 293 means that these are optimal times for defecation. Many constipated 
patients report postponing defecation because of lack of time or opportunity to respond to 
these physiological stimuli. There is good evidence that education and changes in behavior can 
often substantially improve constipation294. Furthermore, deliberately avoiding defecation in 
return for a reward can induce all the symptoms of constipation including hard infrequent 
stools 295.  
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Diet is also a key risk factor. The Nurses Health Study of 62,036 women aged 36-61 
years showed that “high fiber” intake reduced the risk of constipation267. More recent studies 
support this association296.  Regular exercise is associated with a significantly reduced risk of 
constipation267, 297.  Such surveys are of course not controlled studies and are subject to 
confounding by other factors such as comorbidities and drugs. However, one small RCT of 12 
weeks exercise program showed a significant benefit298.  
 An influential nursing home survey found that decreased fluid intake was a risk factor 
for developing constipation following admission299. However, decreased fluid intake is 
associated with many other factors including general frailty and inadequate food consumption. 
Several small RCTs have shown that while severe water restriction (2500 ml/day reduced to 
<500 ml/day) reduces stool weight by around 30%300 there is no benefit in increasing fluid 
intake in those who are normally hydrated301.  
Motility / Transit 
 Transit studies in constipated subjects, using different techniques, have shown that 
overall transit of colonic contents is slow compared with healthy controls,93, 302 but it should be 
noted that a substantial proportion of patients with severe constipation demonstrate normal 
colonic transit.303 In constipated patients with slow transit, affected colonic regions differ 
substantially, with approximately a normal rate of movement of contents in the ascending 
colon and hepatic flexure but delayed transit in the transverse and left colon in some patients, 
whereas other patients show slow transit in both the right and left sides of the colon.304 In 
some patients with severe constipation there are more widespread transit alterations in the GI 
tract. Moreover, by using pancolonic spatiotemporal mapping it was recently possible to show 
regional deficiencies in, and disorganization of, colonic propagating pressure waves in severe 
constipation.305 
Visceral Sensitivity  
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 Visceral perception is increased in a subset of IBS patients but is less well studied in 
patients with FC. Sensory thresholds and compliance to rectal barostat testing were evaluated 
in FC patients (Rome III criteria; n=11), and IBS-C patients (n=23) and compared with healthy 
volunteers (n=23).5 No group differences in perceptual thresholds for first sensation and stool 
sensation were identified, but there was a significant difference in pain threshold. IBS-C 
patients had a lower pain threshold (i.e., increased rectal sensitivity) compared with patients 
with FC and controls. Although there was no significant difference between the latter two 
groups, three (27%) of the constipation patients were considered “hyposensitive” based on the 
2.5 and 97.5 percentiles for controls. The remainder were within the normosensitive range. 
Taken together with other studies, compared with some IBS patients, FC patients do not have 
increased rectal sensitivity and some may be hyposensitive. Limited data suggests that rectal 
sensitivity does not differ between normal transit and slow transit constipation.303  
Enteric Nervous System / Interstitial Cells of Cajal  
Disorders of smooth muscle, the ENS, its neurotransmitters and receptors, or the CNS-
ENS axis may cause severe constipation. In a proportion of patients with severe slow transit 
constipation, clinical signs of autonomic dysfunction can be seen.306 Some patients have 
morphological changes within the myenteric and submucosal plexus,307 and there are also 
histologic studies showing abnormal numbers of myenteric plexus neurons involved in 
excitatory or inhibitory control of colonic motility, with decreased amounts of the excitatory 
transmitter substance P308 and increased amounts of the inhibitory transmitters vasoactive 
intestinal polypeptide (VIP) or nitric oxide (NO).309  Other studies have demonstrated reduced 
numbers of colonic enteroglucagon- and serotonin-containing endocrine cells in constipated 
patients.310 
Interstitial cells of Cajal (ICCs) are the intestinal pacemaker cells and play an important 
role in regulating gastrointestinal motility.311 Confocal images of ICCs in patients with slow-
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transit constipation show not only reduced numbers but also abnormal morphology of ICCs, 
with irregular surface markings and a decreased number of dendrites. In patients with slow-
transit constipation, the number of ICCs has been shown to be decreased in the sigmoid 
colon312 or the entire colon.313, 314 Pathologic examination of colectomy specimens from 
patients with severe intractable constipation revealed decreased numbers of ICCs and 
myenteric ganglion cells throughout the colon.315 
 Serotonin  
Higher combined fasting and postprandial platelet-depleted plasma serotonin 
concentrations were identified in FC patients compared with IBS-C patients and, to a lesser 
extent, healthy controls.5 Overall, serotonin concentrations correlated positively with rectal 
sensory thresholds and inversely with stool frequency. These findings suggest that, in addition 
to playing a role in colonic transit, serotonin’s influence on rectal sensitivity may play a role in 
decreasing perception and evacuation of rectal contents in patients with FC.  
Dyssynergia  
Dyssynergic defecation is a defecatory disorder that causes constipation symptoms 
due to a failure to effectively empty the rectum because of an inability to coordinate 
abdominal, rectoanal, and pelvic floor muscles. Some patients inappropriately contract the 
external anal sphincter and puborectalis muscles when bearing down, while in other patients, 
these muscles incompletely relax during defecation. In addition, there may be inadequate 
rectal propulsive forces needed to expel stool.270 The cause of dyssynergia is not well 
understood but is thought to be due to maladaptive learning of sphincter contraction that 
could develop from avoiding pain and discomfort associated with the passage of large, hard 
stools. In one study, 50-60% of patients were found to have impaired rectal sensation316. In 
addition to dyssynergia, chronic constipation can be caused by other defecatory disorders 
including rectocele, descending perineum syndrome, intussusception and rectal prolapse. 
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Further details can be found in the Anorectal Disorders chapter. 
Psychological Features 
  There is no specific psychological feature or personality that is associated with 
constipation, but constipation reporting, stool output and gut dysmotility may be affected by 
personality, stress and early toilet training.317 Patients with severe constipation and normal 
intestinal transit often have increased psychological distress,317 and may have misperceptions 
about their bowel frequencies.318 Moreover, abnormal illness behavior and locus of control is 
more common in patients with chronic constipation compared with non-patients.319 
 Constipation behavior can be learned in early life. A child may learn to contract the 
sphincters to retain stool to avoid defecation.317 Some data also suggest that faulty toilet 
training produces anorectal disorders such as pelvic floor dyssynergia and encopresis.320 
Deliberate suppression of defecation leads to reduced stool frequency and weight and 
increased transit time.295 Suppression of defecation is common, and in a quarter of subjects 
the urge may not return for several hours.321 
 Treatment 
General Measures  
   Rendering a confident diagnosis, while providing both education and reassurance are 
the cornerstones of management, particularly in a patient who fears that failure to evacuate is 
harmful or represents an underlying life-threatening disease such as colon cancer. Other 
measures such as acting on the call to defecate and in some cases scheduling visits to the toilet 
are often suggested, although no data from controlled trials exists to support these 
recommendations.  Defecation may be facilitated by elevating the feet with a foot stool or 
using a toilet that is lower to the ground.  There is indirect evidence that increased fluids and 
physical exercise is beneficial in patients with constipation322. It is important to carefully 
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scrutinize a patient’s supplements (i.e., vitamins, herbs) as well as over-the-counter and 
prescription medications for potential causes of constipation.  
   When empiric medical treatment fails after an appropriate clinical trial (i.e., 4-8 
weeks), detailed physiological testing should be performed to identify the most appropriate 
treatment.  For example, a patient with dyssynergic defecation by anorectal manometry and 
balloon expulsion test would be most appropriately treated with anorectal biofeedback.  
Peripherally Acting Agents 
Fiber Supplementation and Bulk Laxatives 
   Most treatment guidelines recommend a trial with dietary fiber or a fiber supplement 
if dietary and lifestyle modifications are not effective, before considering laxative therapies or 
physiological testing202, 270 Differences in solubility and fermentation are linked to different 
proposed mechanisms by which fiber influences GI function and in turn, symptoms323. 
Insoluble, non-fermentable fiber accelerates transit by increasing stool biomass leading to 
direct stimulation of secretion and motility. Soluble, more fermentable forms of fiber are 
thought to accelerate transit though their water holding properties and as a consequence of 
the osmotic effects of fermentation by-products, most notably, short chain fatty acids. 
Secondary effects of fiber and its fermentation on the fecal microbiome, mucosal immune 
activation, and /or permeability could also modulate GI function and sensation323.  
   Many patients with mild constipation improve with fiber.  Total fiber intake of 20-30 
grams per day is recommended. For fermentable fiber, dose-dependent bloating, distention, 
and flatulence can affect tolerability and compliance. It is important to instruct patients to 
“start low and go slow”, up-titrating the dosage of fiber in increments over the course of 
weeks.  There is limited data to suggest that constipated patients with severely delayed colon 




  Osmotic laxatives create an intraluminal osmotic gradient which encourages net water 
and electrolyte secretion resulting in reduced stool viscosity and increased fecal biomass with 
secondary effects on peristalsis. These physiological effects underlie improvements in 
constipation270. Given the efficacy, safety, and relatively low cost, many authors consider 
osmotic laxatives as the next most logical choice after fiber for patients with CC202, 270. 
  Unabsorbed mono/disaccharides and sugar alcohols: The osmotic properties of 
lactulose, lactitol, mannitol and sorbitol benefit patients with constipation324 325.  These agents, 
which are not absorbed by the human small intestine, are rapidly fermented by colon bacteria 
to short-chain fatty acids326  The best evidence supporting the use of these agents exists for 
lactulose, which at doses of 15-30 ml once to twice a day can improve symptoms of mild to 
moderate constipation.201 Side effects include dose-dependent abdominal cramping and 
bloating325.  Lactulose appears to be a safe choice for pregnant women with constipation.   
   Saline Laxatives: Incompletely absorbed salts such as magnesium citrate, magnesium 
sulphate, and sodium & disodium phosphate cause the flux of water into the small intestine 
and colon.  Though there is little evidence from randomized, controlled trials, these agents are 
commonly used by patients and generally safe when used in recommended doses. Excessive 
use may lead to electrolyte imbalances, particularIy in the elderly or among patients with renal 
impairment327. 
   Polyethylene glycol (PEG) creates an osmotic gradient which draws fluid and 
electrolytes into the intestinal lumen.  Evidence from high quality, randomized, controlled 
trials of up to 6 months demonstrate its efficacy in patients with chronic constipation 328  Low 
doses are superior to placebo 329 and lactulose 330 in adults and children331. A recent trial found 
that PEG was non-inferior to the prokinetic agent, prucalopride 332. PEG is generally well 
tolerated; the adverse events most commonly reported include distention and diarrhea.   
 Stimulant Laxatives 
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   Stimulant laxatives include diphenylmethane derivatives, such as bisacodyl, sodium 
picosulfate and conjugated anthraquinone derivatives, including cascara sagrada, aloin and 
senna. They decrease water absorption and stimulate intestinal motility and prostaglandin 
release333-335.  Sodium picosulphate (bisacodyl conjugated with sulphate) and the 
anthraquinone derivatives are cleaved by bacteria in the colon, where the active agent may 
stimulate enteric nerves. High quality, 4 week, randomized, controlled trials have 
demonstrated clinical benefits for stool frequency and other constipation associated 
symptoms with bisacodyl and sodium picosulphate in patients with chronic constipation336, 337. 
No large randomized, controlled trials have evaluated anthraquinones for the treatment of 
chronic constipation. At recommended doses, these drugs appear to be generally safe 
although no long term safety data is available. The most common side effects are abdominal 
pain (24.7% v. 2.5% placebo) and diarrhea (53.4% v. 1.7% placebo)336, 337.  Melanosis coli, a 
brown mucosal discoloration, is a harmless, reversible consequence of prolonged 
anthraquinone intake that results from apoptosis of colonic epithelial cells and deposition of 
pigment in macrophages 338-340. 
Prosecretory Agents (Secretagogues) 
   In 4 week, randomized controlled trials of patients with chronic constipation, 
lubiprostone (24 mcg twice daily with food) proved superior to placebo for increasing stool 
frequency, improving stool consistency, reducing straining and overall constipation 
symptoms341-343. The most common adverse events reported in the clinical trials were nausea 
(31% of patients) and diarrhea.   
   In 12 week, randomized, controlled trials, linaclotide 145 mcg once daily was more 
effective than placebo at increasing stool frequency, improving stool consistency, straining and 
overall constipation symptoms in patients with chronic constipation344.  The most common 
treatment associated side effect was diarrhea (16% v. 5% placebo)344. 
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  Results from a dose ranging trial with plecanitide suggest that 3 mg once daily may also 
be effective for functional constipation.345    
Bile Acid Modulation 
  Elobixibat is a nonabsorbed, small molecule that inhibits ileal bile acid transporters, 
thereby increasing delivery of bile acids to the proximal colon which exerts effects on colonic 
secretion and motility. Elobixibat has been found to improve stool frequency and other 
constipation associated symptoms in patients with chronic constipation.  The most commonly 
reported adverse events have been dose-dependent abdominal pain and diarrhea346-348. 
Elobixibat is undergoing evaluation in chronic constipation and IBS-C patients in North America 
in phase III trials. 
Enemas and Transanal Irrigation  
  Enema volume stimulates the rectum to defecate and may be effective in patients with 
constipation due to disordered defecation or megacolon 349.  Phosphate enemas also have an 
intracolonic osmotic effect. Whether phosphate enemas offer any benefit over tap water 
enemas has not been evaluated. The long-term safety of chronic enema use is unknown.  
 Transanal irrigation is a technique in which scheduled water irrigation sessions are 
utilized to evacuate stool from the rectum and distal colon. This technique has demonstrated 
benefits in patients with medically refractory constipation, most commonly in the setting of 
spinal cord injury or neurogenic bowel disorders (i.e., multiple sclerosis or Parkinson’s 
disease)350, 351.   
Surgery 
  Subtotal colectomy with ileorectal anastomosis is a therapeutic option in the rare 
patient with severe, medically refractory, colonic inertia. However, these cases should not be 
considered as FC. Moreover, normal gastric emptying, small bowel motility and anorectal 
function should be established prior to surgery. Approximately 50% to 90% of these patients 
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note symptom improvement, although complications are common, including small bowel 
obstruction (approximately 1/3 of patients), diarrhea, incontinence, and recurrence of 
constipation. Although stool frequency often improves, other symptoms including bloating and 
abdominal pain may not 352 353. Therefore, abdominal colectomy with ileorectal anastomosis 
should only be performed in patients with normal gastric and small bowel motility when all 
non-surgical treatments have been exhausted.  
Systemically Acting Agents 
Prokinetic Agents  
   5-HT4 receptor agonists stimulate peristalsis 354 and accelerate gastrointestinal transit 
355, 356. Tegaserod, a highly selective, partial 5-HT4 receptor agonist, was found to be superior to 
placebo at improving stool frequency and other constipation associated symptoms 357, 358. 
Tegaserod was withdrawn from the USA and most other markets in 2007 due to concerns 
involving possible cardiovascular adverse events.  
   Prucalopride is a dihydrobenzofurancarboxamide derivative with greater selectivity for 
the 5-HT4 receptor compared with other 5-HT4 agonists.  Randomized, controlled trials have 
reported that prucalopride (1-4 mg daily) improves chronic constipation symptoms including 
stool frequency, stool consistency, and straining. The most common adverse events of 
headaches (25-30% v. 12-17% placebo), nausea (12-24% v. 8-14% placebo), and diarrhea (11-
19% v. 3-5% placebo) tended to occur within 24 hours of initiating treatment and were often 
transient 359, 360. 
   The prostaglandin E1 analog, misoprostol (1200 µg/day), was effective in a 3-week 
study, but its long-term efficacy remains unproven.  It is contraindicated in pregnancy. 361 
Complementary and Alternative Medicine (CAM) 
CAM therapies are being increasingly utilized by patients with chronic constipation. 
Dried plums (prunes) contain fiber and non-absorbable carbohydrates including sorbitol and 
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fructans. In an 8-week single-blind, randomized study, prunes (50 grams or roughly 6 prunes 
twice daily) improved stool frequency and consistency when compared with psyllium (p < 0.05) 
362. Hemp seed extract, a Chinese herbal medicine evaluated in patients with FC for 8 weeks 
(7.5 g twice daily), significantly improved stool frequency as well as relief of constipation 
severity and straining when compared with placebo. No serious adverse events were reported 
363.  
  Probiotics might be of benefit to patients with FC, however the quality of the available 
evidence is marginal and the results reported have been conflicting. A systematic review that 
included the results of five RCTs concluded that probiotics may increase stool frequency and 
improve stool consistency in patients with chronic constipation - organisms studied included B. 
lactis DN-173 010, Lactobacillus casei Shirota and E. coli Nissle 1917 364.   
 
C3. FUNCTIONAL DIARRHEA 
Definition 
Functional diarrhea (FDr) is a functional bowel disorder characterized by recurrent 
passage of loose or watery stools.  Patients with FDr should not meet criteria for IBS although 
abdominal pain and/or bloating may be present, but are not predominant symptoms.  
Recurrent passage of loose or watery stool onset should have occurred at least 6 
months prior to diagnosis and symptoms should be present during the last 3 months.   
 
KEY POINTS 
The following points highlight notable changes from Rome III:  
• The term “mushy” has been deleted; it was redundant. 
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• It is specified that abdominal pain and/or bloating may be present but are not 
predominant symptoms (i.e., patients do not meet criteria for IBS). 
 
Epidemiology 
The incidence and prevalence of FDr has not been well investigated, in part because it 
is frequently not distinguished from IBS with diarrhea. Using a matched, case-control 
approach, the incidence of FDr was estimated at 5 per 100,000 patient-years, and a preceding 
infectious gastroenteritis was a significant risk factor.126 
Reported prevalence rates for FDr range from 1.5% to 17%.  Using Rome II criteria, 
prevalence rates for out-patients in Iran were 2%, compared with 3.4% for healthy volunteers 
in Mexico City, and 1.54% in Chinese adults,365-367 Using the validated Bowel Disease 
Questionnaire and excluding patients who met criteria for IBS, one survey study (performed at 
2 time points, 12 years apart), identified prevalence rates of 5.6% and 5.7%,15 while another 
survey study reported a prevalence rate 17%.368  Using Rome III criteria a cross-sectional 
household survey of 18,180 adults conducted in Tehran province identified a prevalence rate 
of 11.1%,369 while a survey study of 4,275 adults in Taiwan identified a prevalence rate of 
2.2%.370 
  The natural history of FDr has not been well characterized. One study reported that 
94% of patients with chronic diarrhea remained symptomatic after 12-20 months of follow-






The following points highlight notable changes from Rome III:  
• 75% of stools being loose has been changed to > 25%.  
 
Diagnosis of FDr  
The diagnosis of FDr should be made based on three key aspects:  1. Clinical history; 2. 
Physical examination; 3. Diagnostic tests. 
1. Clinical History 
 Main symptoms (“Clinical diagnostic criteria”) 
Diarrhea occurs with many gastrointestinal disorders, and is a common reason for 
consulting a physician. Diarrhea should be defined by stool form, not frequency, as stool 
consistency correlates well with colon transit.19 The evaluation should start with a careful 
history. Erratic bowel habits with episodes of constipation, in the presence of abdominal pain 
and/or bloating, is highly suggestive of IBS. A stool diary incorporating the Bristol Stool Form 
Score helps verify stool consistency and excludes pseudodiarrhea.371 A dietary history should 
be taken to exclude lactose and fructose intolerance, and ingestion of excess amounts of fiber 
or poorly absorbed carbohydrates. Post-prandial diarrhea can occur in both FDr and IBS 
patients; however, other disorders (e.g.: celiac disease, Crohn’s disease, rapid colonic response 
C3. Functional Diarrhea 
Diagnostic criteria* 
Loose or watery stools, without predominant abdominal pain or bothersome bloating, 
occurring in at least 25% of stools. 
 





to feeding, food allergies, food sensitivities, carbohydrate maldigestion, SIBO) may cause 
similar symptoms and may warrant evaluation. 47 
Alarm features, such as unintentional weight loss, diarrhea awakening the patient, 
tenesmus (painful urge to defecate), recent antibiotic use, hematochezia (in the absence of 
bleeding hemorrhoids or anal fissures), high-volume diarrhea (>250 ml/day), > 6-10 bowel 
movements per day,1, 372 evidence of malnutrition, or a family history of colorectal neoplasia, 
celiac disease, or inflammatory bowel diseases should prompt further investigation. 
2. Physical Examination 
The physical examination of a patient with FDr should be normal. The clinician should 
look for signs of anemia, clubbing and abdominal tenderness. An abdominal mass suggests 
Crohn’s disease in the young and cancer in the elderly. A careful anorectal examination should 
be performed to assess anal sphincter tone (especially important in patients with 
incontinence) and if the patient has a history of hematochezia (to assess for the presence of 
hemorrhoids or a fissure).  
3. Diagnostic Tests  
A CBC and CRP should be checked in all patients with chronic diarrhea.  A thyroid 
profile can be performed if there is clinical suspicion of hyperthyroidism. Serology for celiac 
disease should be checked in those that fail empiric therapy (and consider EGD with duodenal 
biopsies if antibody tests are positive or if clinical suspicion is high), stool analysis (bacteria, 
parasites and ova) in endemic areas, and fecal calprotectin if clinical suspicion for an 
inflammatory process is high. Giardiasis and tropical sprue should be excluded especially when 
there is a history of acute onset.  
For patients with persistent symptoms, stool specimens can be analyzed for fecal 
elastase-1 and fat, not only because these may identify maldigestive process with moderate 
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sensitivity, but also because a negative test is useful to exclude the need for further 
consideration of maldigestive disorders.48 Colonoscopy can be considered in those who have 
failed empiric therapy, in those with alarm symptoms, and in all patients over age 50 for 
screening purposes (>age 45 in African-Americans). If performed, random biopsies should be 
obtained from both the right and left colon to rule out microscopic colitis. Bile acid 
malabsorption (BAM) is significantly under-recognized and may account for approximately 30% 
of diarrhea previously diagnosed as IBS-D or FDr.373 Unfortunately, confirmatory testing is not 
available in most institutions and requires stool collection and the gammagraphic 
measurement of whole body retention of 75Se-homocholic acid taurine (75SeHCAT). 
Usefulness of Diagnostic  Tests 
In patients with chronic watery diarrhea the functional origin should be considered 
with caution, since in many cases there is an organic cause that justifies diarrhea. This is 
highlighted by the results of a study involving 62 patients with chronic watery diarrhea who 
were carefully investigated using a series of tests; afterwards BAM was considered to be the 
cause of diarrhea in 28 (45%) patients, sugar malabsorption in 10 (16%), gluten-sensitive 
enteropathy in 10 (16%), and both BAM and sugar malabsorption in 2 patients; 12 (19%) 
patients remained without a specific diagnosis and were considered to have functional 
diarrhea. Diarrhea stopped in the 50 patients after specific treatment was initiated, and all 
were without relapse after 12-months of follow-up. 47 
Given the high prevalence of BAM in patents with watery diarrhea an empiric 
therapeutic trial with a BA sequestrant (e.g., cholestyramine or colesevelam) is reasonable. 
Scintigraphic evaluation by the 75SeHCAT test is another option but is not available in many 
countries. Clues to the diagnosis of BAM are sudden-onset, urgency and nocturnal diarrhea, as 
well as increased stool weight,374 but clinical suspicion should not be limited to these cases.  
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Similarly, microscopic colitis (collagenous colitis and lymphocytic colitis) should be 
suspected, especially in the presence of watery diarrhea and/or persistent diarrhea that has 
failed empiric therapy (mainly in women > 50 years of age). There is considerable symptomatic 
overlap between IBS-D, FDr and microscopic colitis. In a population based study of 131 
patients with microscopic colitis, 33% had previously been diagnosed with IBS.44 Positively 
identifying microscopic colitis is relevant since anti-inflammatory therapy, e.g. with 
budesonide375 is effective. 
Carbohydrate (e.g., lactose, fructose, sorbitol) malabsorption is another frequent 
cause of liquid/watery diarrhea.47, 376 Breath tests can be used to make the diagnosis, but if not 




The following points highlight notable changes from Rome III: 
• It is emphasized that patients with chronic diarrhea require a thoughtful evaluation 
before making the diagnosis of FDr. 
• Indications for colonoscopy (and biopsies) have been added 




No single pathophysiological abnormality can explain the cause of FDr in every patient. 
As in other FBDs, diverse mechanisms seem to contribute, including altered gastrointestinal 
motility, brain-gut disturbances, genetic and environmental factors, prior infections and 
psychosocial factors, among others.377 In fact, IBS-D and FDr overlap in 28% of cases when 
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mutual exclusivity is suspended.378 However, patients are more likely to be younger, female, 
anxious and report somatization-type behavior in IBS-D, whereas only loose, mushy or watery 
stools are more common in FDr. 378 
Genetic susceptibility similar to that found in IBS-D is present in FDr, although data is 
limited. For example, the tryptophan hydroxylase 1 (TPH1) promoter SNP-347C/A differentially 
binds EGR-1 and this correlates with IBS bowel habit subtypes; the CC genotype is more 
prevalent in IBS-D (47%) than in IBS-C (25%) and IBS-M (37%) subtypes.379 Conversely, genetic 
variants in CDC42 and NXPH1 are susceptibility factors for IBS subtypes: Rs2349775 (NXPH1) 
and rs17837965 (CDC42) were associated with IBS-D and IBS-C, respectively, in two 
independent cohorts.380 
Gastrointestinal motor disturbances are thought to be the main cause of FDr. 
However, few studies have specifically addressed the pathophysiology of FDr or even 
considered it as distinct from IBS. More than 20 years ago it was reported that fasting and 
postprandial colonic propagating contractions are increased in FDr, whereas nonpropagating 
contractions are increased in healthy volunteers but minimally in patients with diarrhea.381  
Unlike IBS, no studies of rectal sensation  have been performed in FDr, although a pilot study 
showed normal left colonic tone during fasting and a reduced duration of increased colonic 
tone postprandially.382 
Similar to IBS, where approximately 7% of acute infectious gastroenteritis patients 
later develop IBS, either a bacterial or viral infection can lead to post-infectious FDr.128, 383 
Unlike IBS-D, however, no studies have investigated the role of disrupted tight junctions or 




While anxiety often accompanies IBS, few data apply specifically to FDr. Epidemiologic 
research identified an association between chronic diarrhea and self-reported stress in the 
general population. Moreover, acute stress accelerates colonic transit in humans and 
animals,384 but the relevance of this finding to chronic stress, and to FDr patients, is uncertain.  




There are very few studies which have evaluated treatment in patients with FDr. Data 
from studies in patients with other conditions like IBS-D tend to be extrapolated to the 
treatment of patients with FDr. 
Diet 
A thorough diet history and diary is critical to help identify potential triggers.  Clinicians 
often employ specialized diets (e.g. elimination diet), or diets designed to treat IBS symptoms 
(e.g. gluten-free or low FODMAP), although none of these have been tested in FDr patients.157, 
209, 210, 376, 386-391  
Peripherally Acting Agents 
Fiber 
 Some patients may note improvement in stool consistency using methylcellulose or 
fiber products, although appropriate studies to guide clinical care have not been performed in 




The synthetic peripheral opioid agonist loperamide reduces intestinal transit thereby 
increasing intestinal water and ion absorption.  Loperamide improves stool frequency and 
consistency as well as urgency and incontinence in patients with FDr and IBS-D.228-230 
Loperamide may result in some improvement in anal sphincter tone, given the effects of 
opioids on smooth muscle tone (please see OIBD section for a discussion of physiology).  
Bile Acid Binders 
Cholestyramine improves diarrhea symptoms in patients with bile acid malabsorption 
but may also be effective in some patients without bile acid malabsorption 225, 392  Colesevelam, 
improves IBS diarrhea symptoms and may be better tolerated, although it has not been 
assessed in FDr patients225 225. 
Systemically Acting Agents 
Antidepressants 
Tricyclic antidepressant agents (TCAs) have anticholinergic effects which slow intestinal 
transit time and therefore may be effective in patients with FDr, although studies have not 
been conducted.  
5-HT3 Antagonists 
The 5-HT3 antagonist alosetron has been proven to be effective in treating women 
with IBS-D. 393 Another 5-HT3 antagonist, ondansetron, which is widely used as an antiemetic, 
was recently shown to improve stool consistency, frequency, and reduce urgency but not 
abdominal pain in patients with IBS-D.236 Although theoretically enticing, neither of these 
agents have been studied in FDr.  




Probiotics appear to improve symptoms associated with IBS, including diarrhea242, 
though their effects in FDr remain unclear.  
Antibiotics 
A meta-analysis of 5 clinical trials with rifaximin found improvement in global IBS 
symptoms and bloating, but no significant effect on bowel function.202 The role of rifaximin, as 
well as other antibiotics, in FDr remains unclear.   
 
 C4. FUNCTIONAL ABDOMINAL BLOATING/DISTENSION  
Definition  
Functional abdominal bloating/distension (FAB/D) is characterized by symptoms of 
recurrent abdominal fullness, pressure, or a sensation of trapped gas (FAB), and/or   
measurable (objective) increase in abdominal girth (FAD). Patients should not meet criteria for 
other functional bowel disorders although mild abdominal pain and/or minor bowel movement 
abnormalities may co-exist.   
Symptom onset should be at least 6 months prior to diagnosis and the predominant 
symptom (bloating or distension) should be present during the last 3 months. 
   
KEY POINTS 
The following points highlight notable changes from Rome III:  
• “Abdominal fullness, pressure or a sensation of trapped gas” has been included 
 
Epidemiology      
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 Bloating is a commonly reported symptom, both in the general community and in 
patients with other functional gastrointestinal disorders (FGIDs). The incidence of functional 
bloating has not been evaluated in large prospective studies. The prevalence of bloating is 
better described. A large (n = 2,510) telephone survey of U.S. adults reported that 15.9% had 
symptoms of bloating or distension in the month prior to the interview.394 Women were more 
likely to report bloating than men (19.2% vs. 10.5%), and were twice as likely to rate their 
bloating as severe (23.8% vs. 13%).  Older individuals (> 60 years of age) were less likely to 
report symptoms of bloating and distention than younger individuals.  Two other large 
prospective studies of US adults identified similar prevalence rates of bloating (21% and 
19%).395, 396 Using Rome III criteria, the prevalence of functional bloating in the general 
population of Iran was reported to be 1.5%. This figure is likely much lower than other 
reported studies as patients with other FBDs were excluded.369  
Patients with FGIDs are more likely to report co-existing symptoms of bloating. In the 
IBS population, 66% to 90% of patients report bloating.397-399 Bloating is typically more 
common in patients with IBS-C than IBS-D and is more prevalent in women than men.396, 399-401  
In a cross-sectional study of over 16,000 Chinese adults, bloating was more prevalent (21%) in 
patients with functional constipation than those without constipation symptoms (OR = 8.44; 










Diagnosis of FAB/D 
FAB/D should be diagnosed based on three aspects:  1. Clinical history; 2. Physical 
examination; 3. Minimal/limited diagnostic studies.  
1. Clinical History 
Main symptoms (“Clinical diagnostic criteria”) 
The evaluation of a patient with abdominal bloating and/or distension should begin 
with a careful history, which includes the onset of symptoms, the relationship to diet (e.g., 
wheat, dairy, fructose, fiber, non-absorbable sugars) and bowel habits, and the presence of 
symptoms suggestive of other functional GI disorders. Alarm features, such as anemia and 
unintentional weight loss, should be assessed, as these symptoms may be a sign of a 
malabsorptive process. If present, the clinician may initiate a diagnostic evaluation (see 
C3.  Functional Abdominal Bloating/Distension 
Diagnostic criteria* 
1. Recurrent bloating and/or distension occurring on average at least 1 day/week; 
abdominal bloating and/or distension predominates over other symptoms#.  
2. There are insufficient criteria for a diagnosis of irritable bowel syndrome, functional 
constipation, functional diarrhea or post-prandial distress syndrome. 
# Mild pain related to bloating may be present as well as minor bowel movement 
abnormalities. 





below).  Patients complaining of bloating along with another symptom should be evaluated 
accordingly.  
Sufferers of bloating and/or distension typically report worsening as the day 
progresses, particularly after meals, but with alleviation of symptoms overnight.403, 404 In tape 
measure studies of abdominal girth to assess distension, diurnal worsening of bloating is 
accompanied by increased girth.405 Studies performed with abdominal inductance 
plethysmography, which permits objective ambulatory measurement of abdominal girth 
throughout the day, have confirmed that abdominal girth increases during the day in most 
patients with IBS and to a greater extent than in healthy volunteers.406 However, the symptom 
of bloating only correlates with increased abdominal girth in constipated patients,10 suggesting 
different, constipation-related pathophysiological mechanisms. Thus, functional bloating is 
typically diagnosed after constipation and sugar maldigestion are excluded. Bloating alone (not 
bloating with distension) is associated with rectal hypersensitivity, whereas bloating with 
distension (but not bloating alone) is associated with prolonged colonic transit relative to 
patients with bloating alone.407, 408 In addition, reduction in abdominal girth overnight,11 as well 
as difficulties with rectal gas expulsion409 in patients with bloating, suggest there may be a 
significant contribution of abnormal rectal gas evacuation to symptoms of bloating.  
2. Physical Examination 
Bloating (subjective) and distension (objective) should be differentiated. The term 
abdominal distension should be reserved for patients who show a visible increase in 
abdominal girth. Evidence of a partial bowel obstruction or organomegaly warrants further 
evaluation. A pelvic examination should be performed when appropriate. 
3. Diagnostic Tests 
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Validated guidelines for the evaluation of bloating do not exist. Many clinicians favor 
empiric therapy in the absence of warning signs. Alternatively, limited testing may be useful. 
An abdominal x-ray can be performed to evaluate for possible obstruction. A serum IgA and 
TTG antibody can be used to evaluate for celiac disease. Small intestinal bacterial overgrowth 
can be evaluated by culturing the jejunal aspirate or by performing a breath test, preferably 
with glucose.409 A CBC should be performed if there are warning signs of anemia. If the clinical 
suspicion for celiac disease is high, upper endoscopy with duodenal biopsies should be 
performed.    
Physiologic Features 
Bloating and distension are commonly thought of as synonymous terms. However, 
accumulating evidence has demonstrated that these processes have different 
pathophysiologic underpinnings and thus should be considered distinct entities, although they 
commonly overlap.408  It is important to note that research in this area has been problematic in 
part due to linguistic differences. Thus, for the purpose of this monograph, bloating and 
distention will be defined as noted above. 
The pathophysiology of bloating remains incompletely understood for a number of 
reasons (see Figure 7 below). One, the underlying pathophysiologic process (or processes) is 
likely different amongst the various FGIDs. Two, the etiopathophysiology of bloating varies 
from patient to patient, even within the same FGID subcategory. Three, bloating is a complex 
process and frequently represents a number of different processes, all of which produce the 
same symptom. Potential causes of functional bloating include visceral hypersensitivity, 
abnormal intestinal gas transit, impaired evacuation of rectal gas, colonic fermentation of 
different food products, small intestine bacterial overgrowth, an abnormal abdomino-
diaphragmatic reflex, and disorders (both qualitative and quantitative) of the gut 
microbiota.267  Contrary to popular opinion, most patients with FGIDs do not have more 
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intestinal gas than healthy volunteers.410 However, IBS patients report more bloating and 
distension than healthy volunteers with similar levels of intestinal gas infusion, and IBS-C 
patients may retain gas longer than IBS-D patients.411, 412 These studies highlight the facts that 
visceral hypersensitivity407 and impaired intestinal transit and evacuation are responsible for 
bloating symptoms in some FGID patients.  
The pathophysiology of abdominal distension in patients with FGIDs is better 
understood due to innovations in technology, including abdominal inductance 
plethysmography, a novel technique that can measure abdominal distention.  Elegant studies 
from several research groups have demonstrated that an abnormal viscero-somatic reflex, 
involving the diaphragm and the abdominal wall muscles, is responsible for the symptom of 
distension in many FGID patients. Specifically, stretch and distention of the luminal intestinal 
tract - from gas, liquids, or solids - leads to an abnormal contraction of the diaphragm (rather 
than relaxation) along with relaxation (rather than contraction) of the abdominal wall muscles 
(the rectus and external oblique). This abnormal reflex causes visible abdominal distension, in 
contrast to healthy volunteers, where diaphragmatic relaxation and contraction of the 
abdominal wall muscles prevents or minimizes abdominal distension.413 The precise etiology of 
this abnormal viscero-somatic reflex is not known; one study of IBS patients identified a 
relationship with rectal hyposensitivity.407 Abdominal distension in FGID patients frequently 
occurs in conjunction with sensations of bloating, although it may occur independently. Other 
factors play a role in visible abdominal distension, most notably slower intestinal transit,406 in 










Figure 7. Pathophysiology of functional abdominal bloating and distension. 
Psychological Features 
Large questionnaire studies to identify co-morbid psychological disorders in patients 
with FAB/D are not available. 
Treatment 
Most studies have evaluated abdominal bloating in patients with other FGIDs and 
therefore may not have been sufficiently powered to detect significant differences.   
Diet 
Foods that are poorly absorbed and highly fermentable are commonly associated with 
increased gas and bloating.  Some patients with IBS and bloating note an improvement in 
symptoms when placed on a diet low in FODMAPs.209, 210 Similarly, some IBS patients note an 
improvement when treated with a gluten free diet. Neither approach has been used 





Peripherally Acting Agents 
Laxatives  
A recent trial in IBS-C patients using polyethylene glycol plus electrolytes for 28 days 
found no significant reduction in bloating compared with placebo (p=0.06).213 
Prosecretory Agents (Secretagogues) 
In 2 phase III studies in IBS-C patients bloating improved with lubiprostone (8 mcg 
twice daily) compared with placebo218. Similarly, linaclotide also improved bloating symptoms 
in the phase III studies for chronic idiopathic constipation344 and IBS-C220, 221.  A recent trial with 
CC patients who had predominant bloating showed significant reductions in bloating 
symptoms415. 
Gas Reducing Substances 
Simethicone, an anti-foaming agent, was reported to improve the frequency and 
severity of gas, distension and bloating in one small study involving 41 patients with upper 
gastrointestinal symptoms416. α-galactosidase, derived from Aspergillus niger mold, acts to 
break down non-absorbable oligosaccharides before they are metabolized by colonic bacteria.  
In healthy volunteers fed a meal high in oligosaccharides, α-galactosidase improved symptoms 
of gas and bloating.417  In pediatric patients (age range 4-17 years) complaining of gas-related 
symptoms, α-galactosidase reduced global distress, the number of days with moderate to 
severe bloating, and the proportion of patients with flatulence compared with placebo 418 




Among the antispasmodics, peppermint oil has been most extensively studied.  One 
study demonstrated that peppermint oil, taken three to four times a day, 15-30 minutes 
before meals for four weeks, resulted in a significant decrease in abdominal distention 
compared with placebo419. In another study peppermint oil twice daily for 4 weeks decreased 
bloating and distention420.  
Antidepressants 
In patients with moderate to severe functional bowel disorders, desipramine in 
conjunction with cognitive behavioral therapy resulted in an improvement in bloating although 
the effects of desipramine alone on bloating remain unclear421. A small, crossover-trial with 
citalopram showed an improvement in the number of days without bloating at 3 and 6 
weeks422. 
Prokinetic Agents 
In a study of 28 patients with abdominal bloating, intravenous neostigmine caused 
immediate clearance of infused jejunal gas compared to placebo411.  However, in patients with 
IBS and bloating, pyridostigmine (p.o.) provided only minimal improvement in bloating 423. 
Microbiome and Immune Modulation 
Probiotics 
A recent meta-analysis of probiotics in IBS found overall improvement in symptoms of 
bloating. Bloating scores were significantly reduced with probiotics (SMD = −0.15; 95% CI −0.27 
to −0.03), with no significant heterogeneity between individual study results 
(I2=16%, P=0.26)242.  However, the optimal strain, dose, frequency and duration of probiotic 
use remains unclear.  
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Significant improvements in objectively measured abdominal girth as well as reduced 
symptomatology were observed in a randomized, double-blind, controlled, parallel group 
study comparing a fermented dairy product containing Bifidobacterium lactis DN-173 010 and 
a control product in IBS-C patients.241 
In women with IBS, Bifidobacterium infantis 35624 at a dose of 1 × 108 CFU/mL 
improved bloating symptoms more than placebo240.  Similarly, in patients with non-
constipated functional bowel disorders, Lactobacillus acidophilus 
and Bifidobacteriumlactis reported improvement in bloating severity 424. The combination 
probiotic VSL#3 has been shown to reduce bloating in children, although the results in adults 
have been less impressive 425-427. 
Antibiotics  
In a double-blind, randomized, placebo-controlled trial of 124 patients with 
predominant bloating and excessive flatulence with negative lactulose hydrogen breath tests, 
rifaximin (400 mg p.o. twice daily for 7 days) improved global symptoms and bloating scores 
compared with placebo 428. Rifaximin (400 mg three times daily for 10 days) also reduced 
bloating severity during a 10-week follow-up period 429. Finally, 2 phase III trials found that 
rifaximin, at a dose of 550 mg three times daily for 14 days in patients with non-constipation 
IBS, provided greater adequate relief of bloating compared with placebo  (40% vs. 30%, 
p<0.05)243.  
C5. UNSPECIFIED FUNCTIONAL BOWEL DISORDERS  
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In some cases, a patient may not fulfil diagnostic criteria for any of the 4 specific FBDs 




OPIOID-INDUCED BOWEL DISORDERS  
Since the Rome III criteria were published significant advances have been made in the area of 
opioid-induced bowel disorders (OIBD). These disorders are becoming more prevalent with the 
increasing use of opioids. Although this committee does not consider OIBD a functional 
gastrointestinal disorder, we recognize that OIBD may overlap with any of the FBDs described 
above. In addition, further advances in knowledge over the next decade may elucidate shared 
pathophysiologic or psychologic processes. For these reasons, a brief description of OIBD is 
provided below (the reader is also referred to the appropriate sections for a discussion on 
narcotic bowel syndrome (NBS) and cannabis hyperemesis syndrome (CHS)).    
  
Definition  
C5.  Unspecified Functional Bowel Disorder 
Diagnostic criteria* 
Bowel symptoms not attributable to an organic etiology that do not meet criteria for 
the four previously defined functional bowel disorders 
 
* Criteria fulfilled for the last 3 months with symptom onset at least 6 months 




Opioid induced bowel disorders (OIBD) refers to a spectrum of disorders, which develop as a 
result of opioids acting both on the gastrointestinal tract and in the central nervous system.  
With the exception of nausea and vomiting, which are at least in part centrally mediated, 
symptoms and signs of OIBD reflect the segment of the GI tract involved.  One of the most 
common OIBDs is opioid-induced constipation, which is defined and described below.  
Criteria for OIBD: A symptom complex that develops with opioid use and which reflects the 
impact of opioids on the GI tract, including hard stools, infrequent stools, incomplete 
evacuation, bloating, abdominal pain, nausea and vomiting.  
 
Opioids are increasingly being used to treat cancer- and non-cancer related chronic pain.  
As opiate use has increased, so has the recognition that these agents have a number of 
adverse effects on the GI tract.  Opioid-induced effects on the GI tract should not be 
considered a distinct FGID but rather should be categorized as an opioid-induced adverse 
effect. However, given the high prevalence of FGIDs it is important to recognize that not all 
gastrointestinal symptoms in a patient taking opioids are directly related to opioids. Thus, 
Opioid Induced Constipation  
 
Diagnostic criteria 
I.New, or worsening, symptoms of constipation when initiating, changing, or increasing 
opioid therapy, that must include two or more of the following:  
a. Straining during at least ¼ (25%) of defecations; 
b. Lumpy or hard stools (Bristol Stool Form Scale 1-2) at least ¼ (25%) of defecations; 
c. Sensation of incomplete evacuation at least ¼ (25%) of defecations; 
d. Sensation of anorectal obstruction/blockage at least ¼ (25%) of defecations; 
e. Manual maneuvers to facilitate at least ¼ (25%) of defecations (e.g., digital 
evacuation, support of the pelvic floor);  
f. Fewer than three SBM per week. 
 





functional constipation may overlap with, or exacerbate, opioid-induced constipation (OIC; and 
visa versa). The marked rise in the prevalence of opioid-induced disorders clearly signals a 
need for a heightened awareness for all health care providers.  The following sections provide 
a brief overview of this issue. 
Adverse effects of opioids on the GI tract can be broadly classified into NBS and OIBD. 
NBS is characterized by an increase in the severity of chronic abdominal pain despite the use of 
continuous or increasing doses of opioids prescribed for abdominal pain.430 NBS is mediated, to 
a large degree, via changes in the central nervous system (see Chapter 12).431-433 OIBD 
represents a broad spectrum of disorders which can involve any segment of the 
gastrointestinal tract. OIBD occurs when opioid receptors (e.g., mu, kappa, or delta) in the GI 
tract or CNS are activated by either exogenous or endogenous opioids leading to a decrease in 
propulsive activity, an increase in non-propulsive contractions, a decrease in pancreatic, biliary 
and gastric secretions, and an increase in anal tone. These physiologic changes may lead to 
abnormalities in esophageal peristalsis, gastric emptying, small intestine and colon transit, and 
anorectal function.  Thus, depending upon the gut segment involved (e.g., esophagus, 
stomach, small intestine, colon, anorectum), symptoms of OIBD can include reflux, dysphagia, 
nausea, vomiting, early satiety, bloating, distention and constipation.   
The most common OIBD is OIC, which has recently been defined by an expert panel as 
a change, when initiating opioid therapy, from baseline bowel habits and defecation patterns, 
that is characterized by any of the following: a) reduced bowel frequency; b) development or 
worsening of straining; c) a sense of incomplete evacuation; or d) a patients´ perception of 
distress related to bowel habits.434  The occasional patient may also develop fecal impaction 
with overflow incontinence, while others may report symptoms compatible with overlapping 
OIBD (e.g., reflux, nausea, bloating).  The reported prevalence of OIBD ranges from 60- 90% in 
cancer-related opioid use to 40-60% in non-malignant pain patients.435, 436  Not surprisingly, 
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patients with OIC report a significant reduction in quality of life.437, 438  The treatment of OIC is 
similar in many ways to the treatment of functional constipation (see functional constipation 
section above.  Laxatives are recommended for both the prophylaxis and management of OIC 
in patients with cancer by the European Association for Palliative Care.439  Lubiprostone, a 
chloride channel activator, was approved for the treatment of OIC in adults with non-cancer 
pain in 2013. 440 
 Additional treatment options for patients with OIC involve the use of opioid receptor 
antagonists which block opioid actions either centrally or peripherally, thereby minimizing or 
preventing the negative effects of opioids on intestinal secretion and colonic propulsion. 441 
Naloxone and nalbuphine are 2 medications classified as centrally active agents. Since these 
agents cross the blood-brain barrier they may precipitate opioid withdrawal symptoms.442, 443 A 
combination product of an opioid antagonist (naloxone) and an opioid agonist (oxycodone) is 
available in Europe and has received approval for patients with severe pain.  
Agents that specifically block peripheral opioid receptors in the GI tract and not central 
receptors would be clinically advantageous, since they would not lead to symptoms of 
withdrawal. Three such peripherally acting µ-opioid receptor antagonists (PAMORA) are 
currently available. Subcutaneous methylnaltrexone is approved for OIC in patients with 
chronic non-cancer pain and for patients with advanced illness receiving palliative care who 
have had an inadequate response to laxative therapy.444, 445 The European Association for 
Palliative Care (EAPC) guidelines recommend subcutaneous methylnaltrexone as a second-line 
treatment option for OIC in patients with chronic cancer pain when traditional laxatives are 
not effective.439 Alvimopan, available in the United States, but not in Europe, is a PAMORA 
indicated only for preventing or shortening the course of postoperative ileus after bowel 
resection and is therefore available only for hospital use.446 It is not currently approved for use 
in OIC in either Europe or the US. Naloxegol, an oral PEGylated derivative of naloxone, was 
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approved by the FDA for the treatment of OIC in adult patients with non-cancer pain in 
September 2014 (cite 470).   
Drugs in Development for the Treatment of OIC 
 Several additional PAMORA agents with the potential to not compromise pain relief in 
patients taking opioids are currently in development for OIC.441 One randomized, controlled 
trial has demonstrated the efficacy of the 5-HT4 agonist prucalopride (2 mg p.o.) in the 
treatment of OIC.440  An oral formulation of methylnaltrexone is under investigation, and the 
currently available subcutaneous formulation is under consideration for OIC in patients with 
chronic non-cancer pain. Two other medications currently under development for OIC in 
patients with chronic non-cancer pain include: Bevenopran, TD-1211, and N-aldemedine (S-
297995).  Large, prospective, multinational, randomized, placebo-controlled trials are needed 
to assess the efficacy and safety of these agents. 
 
Key Questions for Future Research in Functional Bowel Disorders 
1. What is the validity of the Rome IV FBDs criteria for both clinical research and patient care? 
2. How does the new method of Rome IV subtyping for IBS predict response to treatment? 
3. Are FBDs individual disorders or do they represent a spectrum of disease? 
4. What is the temporal relationship between food ingestion and bowel movements with 
abdominal pain in IBS patients, and does it differ between IBS subtypes? 
5. What are the relative roles of motility, permeability, immune activation, microbiome, 
visceral hypersensitivity and brain-gut interactions in FBDs and how do they interact? 
6. What is the clinical utility of current biomarkers for FBDs? 
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7. Can biomarkers be used to identify patients most likely to respond to specific treatments for 
FBDs?  
8. Which new biomarkers will aid in the diagnosis and treatment of FBDs in clinical practice 
and clinical trials?  
9. Can genetic subtyping predict clinical phenotype and response to therapy? 
10. What are the predictors (e.g. genetics, psychological, physiological, metabolic) of long-term 
outcomes in FBDs? 
11. What are the roles of diet and lifestyle in FBDs? 
12. What are novel treatment targets for abdominal symptoms of FBDs (e.g., abdominal pain 
and bloating)? 
13. What is the relationship of opioid induced constipation (OIC) with FC and can Rome IV 
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Functional constipation features according to the frequency thresholds based on the 
occurrence of these symptoms in the general population. These constipation symptoms are 
notoriously variable in frequency of occurrence in normal people (derived from the Rome 
Survey of the Normal Population). 
a.  Straining during more than 30% of defecations 
b. Lumpy or hard stools (Bristol Stool Form Scale 1-2) on more than 30% 
of defecations 
c. Sensation of incomplete evacuation on more than 30% of defecations 
d. Sensation of anorectal obstruction/blockage on more than 20% of weeks 
e. Manual maneuvers to facilitate more than 10% of defecations 
f. Fewer than three SBM per week for more than 20% of weeks 
 
